冠脉介入术后气虚血瘀证与CYP2C19*2基因多态性的相关性及脑心通胶囊干预作用的研究
|
摘要
第一部分影响冠脉介入术预后的中西医临床危险因素分析
一、目的
探讨影响冠脉介入术(PCI)预后的中西医临床危险因素,观察PCI术后气虚血瘀证对抗栓疗效的影响,并分析PCI术后气虚血瘀证与CYP2C19*2基因多态性的相关性。
二、方法
1.505例行PCI成功的冠心病患者进行术后规范抗栓治疗,根据术后1年是否发生主要心血管事件分为发生组和未发生组,对可能影响PCI预后的中西医临床危险因素进行多因素logistic回归分析。
2.256例行PCI成功的冠心病患者进行术后规范抗栓治疗,术后1周采血检测血小板计数(PLT)、最大血小板聚集率(MPA)、血管性假血友病因子(vWF)、血小板膜糖蛋白Ⅱb/Ⅲa (GPⅡb/Ⅲa)、凝血酶原片段1+2(F1+2)和纤维蛋白原(FIB),同时进行中医辨证分为气虚血瘀证和非气虚血瘀证。
3.505例行PCI成功的冠心病患者进行术后规范抗栓治疗,术后1周根据是否存在气虚血瘀证表型分为气虚血瘀组和非气虚血瘀组,抽取外周静脉血提取DNA,采用PCR-RFLP基因分析方法检测CYP2C19*2基因多态性。
三、结果
1.单因素分析和多因素logistic回归分析显示气虚血瘀证、MPA(≥70%)、血浆vWF水平和CYP2C19*2基因突变是影响PCI术后1年主要心血管事件的独立危险因素(P均＜0.01)。
2.PCI术后气虚血瘀组MPA、vWF、GPⅡb/Ⅲa高于非气虚血瘀组(P均<0.01),而PLT、F(1+2)和FIB两组间差异无统计学意义(P＞0.05)。
3.单因素分析显示：气虚血瘀组CYP2C19*2基因突变型(GA+AA)明显高于非气虚血瘀组(X2=26.952,P<0.01)。多因素logistic回归分析显示：以非气虚血瘀组为参照系,调整诸混杂危险因素后,CYP2C19*2基因突变型(GA+AA)的相对危险度(OR)为2.551(95%C1：1.463-4.446,P=0.001)。
四、结论
1.气虚血瘀证、血浆vWF水平、MPA70%切割点和CYP2C19*2基因突变对评价PCI预后具有重要意义。
2.在目前强化抗栓治疗的基础上,PCI术后气虚血瘀证仍存在明显的血小板活化和血管内皮损伤,但对血小板数量和凝血功能影响不大,是PCI术后1年发生主要不良心血管事件的独立危险因素。
3. CYP2C19*2基因突变可能是PCI术后气虚血瘀证的易患因素之一第二部分验证依据气虚血瘀证和CYP2C19*2基因突变联合分析指导冠脉介入术后个体化抗栓治疗药物选择的作用(前瞻性、随机、单盲、对照临床试验)
一、目的
探讨益气活血的中药复方脑心通胶囊干预PCI术后个体化抗栓治疗的疗效。
二、方法
选取行PCI成功,中医辨证属于气虚血瘀证且CYP2C19*2基因突变型(GA+AA)的冠心病患者54例,采用随机单盲对照法分为治疗组和对照组,各为27例。对照组进行术后规范抗栓治疗,治疗组在术后规范抗栓治疗的基础上加用脑心通胶囊,每次4粒,一天3次,连续使用1个月。观察治疗前、治疗后10天气虚证、血瘀证积分及远近期抗栓疗效,同时评估抗栓治疗的安全性。
三、结果
1.治疗组和对照组两组患者治疗前气虚证和血瘀证积分比较无统计学意义(P>0.05)。与治疗前比较,治疗后10天治疗组气虚证积分明显降低(P＜0.01),而对照组明显升高(P＜0.01),治疗后10天治疗组气虚证积分较对照组降低(P＜0.05)。与治疗前比较,治疗后10天两组患者血瘀证积分均明显降低(P均＜0.01),治疗后10天血瘀证积分治疗组较对照组降低(P<0.05)。
2.治疗前,两组患者PLT、MPA、血浆vWF、GPⅡb/Ⅲa、F(1+2)和FIB比较均无统计学意义(P>O.05)。与治疗前比较,治疗后10天两组患者MPA、血浆vWF、GPⅡb/Ⅲa、F(1+2)和FIB均显著降低(P均<0.01),而PLT无显著性差异(P＞0.05)。治疗后10天,治疗组MPA、血浆vWF、GPⅡb/Ⅲa、F(1+2)和FIB较对照组降低(P均<0.05),而PLT无统计学差异(P>0.05)。
3.两组患者PCI术后1个月终点事件比较发现：对照组3例发生心血管事件,其中2例发生不稳定性心绞痛,1例发生急性心肌梗死；治疗组均未发生心血管事件。根据是否发生终点事件,进行Fisher精确检验,两组差异未见统计学意义(P>0.05),有待继续扩大样本量进行观察。
4.根据PCI术后1个月的随访记录发现,治疗组和对照组在服药期间均无主要出血事件和次要出血事件发生。
四、结论
1.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊能明显降低术后10天的气虚证和血瘀证积分。
2.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊可明显抑制血小板活化,保护血管内皮细胞和改善机体凝血功能。
3.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊有降低术后1个月心血管事件发生的趋势,有待继续扩大样本量进行观察。
4.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊引起血小板减少和出血等药物不良反应可能性小。第三部分脑心通胶囊对人肝微粒体CYP2C19酶活力的影响
一、目的
研究脑心通胶囊对人肝微粒体中CYP2C19酶活力的影响。
二、方法
以美芬妥英为CYP2C19探针药,利用HPLC方法测定美芬妥英的代谢产物4-OH美芬妥英的浓度,研究脑心通胶囊在人肝微粒体孵化体系中对CYP2C19酶活力的影响。
三、结果
在人肝微粒体反应体系中,脑心通胶囊(0-250μg/m1)自150μg/ml开始对CYP2C19有酶促作用,且随着浓度的增加逐渐增强。
四、结论
在人肝微粒体反应体系中,脑心通胶囊(0-250μg/ml)自150μg/m1开始对CYP2C19有酶促作用,且随着浓度的增加逐渐增强。PCI术后气虚血瘀证且CYP2C19*2基因突变的患者在标准抗栓治疗的基础上合用脑心通胶囊有可能通过上述机制增强氯吡格雷抗血小板的疗效,在一定程度上改善氯吡格雷抵抗。
Part I Analysis of the clinical risk factors of Traditional Chinese Medicine (TCM) and Western Medicine affecting prognosis of percutaneous coronary intervention (PCI)
Objective
To research the clinical risk factors of TCM and Western Medicine affecting the prognosis in patients undergoing PCL and observe the effect of qi deficiency and blood stasis syndrome after PCI on antithrombotic treatment, and analyze the relationship between qi deficiency and blood stasis syndrome after PCI and polymorphisms of CYP2C19*2 gene.
Medthods
1.505 CHD patients after receiving successful PCI were adopted in this study.They were divided into with major adverse cardiac events (MACE) group and without MACE group.Multivariate logistic analysis was used to analyze the independent influencing factors of prognosis after PCI.
2.We adopted 256 CHD patients after receiving successful PCI.After 1 week of standard antithrombotic treatment, TCM syndromes were differentiated into qi-deficiency blood-stasis type and non-qi-deficiency blood-stasis type.All patients detected platelet count (PLT) n maximum platelet aggregation rate (MPA)% plasma von Willebrand factor (vWF) n platelet membrane glycoproteinsⅡb/Ⅲa (GPⅡb/Ⅲa)%prothrombin fragment 1+2 (Fl+2) and fibrinogen (FIB)
3.505 CHD patients after receiving successful PCI were adopted in this study. TCM syndromes were differentiated into qi-deficiency blood-stasis type and non-qi-deficiency blood-stasis type after 1 week of standard antithrombotic therament. All patients were genotyped for the polymorphisms of CYP2C19*2 by PCR-RFLP, and the genetic variants frequencies were compared in subjects.
Results
1.The univariate analysis and logistic regression analysis indicated that qi deficiency and blood stasis syndrome^ more than 70% in maximum platelet aggregation rate (MPA)> the level of plasma von Willebrand factor (vWF) and CYP2C19*2 gene mutation were the independent risk factors of MACE in the following 1 year after PCI (P<0.01)
2.Compared with the non-qi- deficiency blood-stasis group after PCI, the MPA、vWF and GPⅡb/Ⅲa were obviously higher in qi- deficiency blood-stasis group (P<0.01), and there were no statistical difference of PLT、F (1+2) and FIB between the two groups (P>0.05)
3.The patient genotype distribution was in Hardy-Weinberg equilibrium. Partitions ofχ2 method showed that GA+AA was higher in qi-deficiency blood-stasis group than in non-qi-deficiency blood-stasis group (χ2=26.952, P<0.01).After adjusting for common risk factors of CHD after PCI, logistic regression analysis indicated that the odds ratios (OR) of GA+AA (vs GG) genotype for qi deficiency and blood stasis syndrome was 2.551 (95%Cl:1.463-4.446, P=0.001) with the reference category of non-qi-deficiency blood-stasis syndrome.
Conclusions
1.Qi deficiency and blood stasis syndrome、70% cut-off in MPA、the level of plasma vWF and CYP2C19*2 gene mutation are very important to evaluate the prognosis for CHD patients after receiving successful PCI.
2.Qi deficiency and blood stasis syndrome after PCI affects platelete activation and ndothelial function on standard antithrombotic treatment, whereas the number of blood platelet and coagulation function may be not. Qi deficiency and blood stasis syndrome is the independent risk factor of MACE in the following 1 year after PCI.
3.The GG+AA genotype may be some heritable susceptibility to disease of qi deficiency and blood stasis syndrome after PCI. PartⅡThe directive effect of conjoint analysis qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation on individualized antithrombotic durg selection after percutaneous coronary intervention (a prospective, randomized, single-blind, controlled clinical trial)
Objective
To investigate the therapeutic effect of nao xin tong capsule on individualized antithrombotic treatment of patients undergoing PCI.
Medthods
54 CHD patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation, who had received revascularization by PCI successfully, were randomized into the treatment group and the control group, both treated with conventional western medical treatment, but the treatment group combined, respectively, with nao xin tong capsule for 1 month.The investigating items included Chinese medicine syndrome scores, short and long-term efficacy and safety assessment of antithrombotic treatment.
Results
l.The baseline between the two groups was similar. Before treatment* there was no significant difference in Chinese medicine syndrome scores (P>0.05). After treatment, qi deficiency syndrome and blood stasis syndrome scores reduced significantly in the treatment group (PO.01) and the control group showed a higher qi deficiency syndrome score and lower depressive amplitude of blood stasis syndrome score (PO.01),while significantly superior to qi deficiency syndrome and blood stasis syndrome scores in the treatment group (P<0.05).
2.Before treatment, there were no statistical difference of PLT、MPA. vWF、GPⅡb/Ⅲa, F(1+2) and FIB (P>0.05). After treatment, the indicators of MPA、vWF、GPⅡb/Ⅲa、F (1+2) and FIB went down in both groups (P<0.01), but the lowering in the control group were lesser (P0.05).The change ofPLT was insignificant between two groups (P>0.05)
3.During the period of one-month follow-up,3 MACE and zero MACE occurred in the control group and the treatment group respectively, no statistical difference was found between them (P>0.05)
4.There was no major and minor hemorrhagic complication in the treatment group and the control group.
Conclusions
1.Nao xin tong capsule may decrease qi deficiency syndrome and blood stasis syndrome scores of ten days after PCI in patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation.
2. Combination of conventional western antithrombotic treatment and nao xin tong capsule shows better efficacy in inhibiting activity of blood platelet%alleviating endothelial cell damage and improving coagulation function.
3.Along with nao xin tong capsule administration, there is a depress tendency for the occurrence of cardiovascular events during one month after PCI in patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation.
4.Combination of conventional western antithrombotic treatment and nao xin tong capsule may not increase the incidence of thrombocytopenia and bleeding complications. PartⅢEffect of nao xin tong capsule on the activity of cytochrome P2C19 (CYP2C19) in human microsome
Objective
To observe the effect of nao xin tong capsule on CYP2C19 activity in human liver microsome in vitro.
Medthod
Mephenytoin (the probe drug of CYP2C19) was incubated with or without nao xin tong capsule in human liver microsome respectively.The concentrations of mephenytoin and its metabolity (4-OH mephenytoin) were determined by HPLC, and the CYP2C19 activity was reflected by the metabolite production (4-OH mephenytoin)
Result
Compared with pre-incubation without nao xin tong capsule, the metabolite concentration of 4-OH mephenytoin had statistical difference in pre-incubation with nao xin tong capsule (150-250μg/ml)
Conclusion
Nao xin tong capsule results in an induction of CYP2C19 activity of in vitro in a dose-depentent manner. The combination of nao xin tong with clopidogrel may be reinforce the effect of antiplatelet through the above-mentioned mechanism in patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation after PCI.
一、目的
探讨影响冠脉介入术(PCI)预后的中西医临床危险因素,观察PCI术后气虚血瘀证对抗栓疗效的影响,并分析PCI术后气虚血瘀证与CYP2C19*2基因多态性的相关性。
二、方法
1.505例行PCI成功的冠心病患者进行术后规范抗栓治疗,根据术后1年是否发生主要心血管事件分为发生组和未发生组,对可能影响PCI预后的中西医临床危险因素进行多因素logistic回归分析。
2.256例行PCI成功的冠心病患者进行术后规范抗栓治疗,术后1周采血检测血小板计数(PLT)、最大血小板聚集率(MPA)、血管性假血友病因子(vWF)、血小板膜糖蛋白Ⅱb/Ⅲa (GPⅡb/Ⅲa)、凝血酶原片段1+2(F1+2)和纤维蛋白原(FIB),同时进行中医辨证分为气虚血瘀证和非气虚血瘀证。
3.505例行PCI成功的冠心病患者进行术后规范抗栓治疗,术后1周根据是否存在气虚血瘀证表型分为气虚血瘀组和非气虚血瘀组,抽取外周静脉血提取DNA,采用PCR-RFLP基因分析方法检测CYP2C19*2基因多态性。
三、结果
1.单因素分析和多因素logistic回归分析显示气虚血瘀证、MPA(≥70%)、血浆vWF水平和CYP2C19*2基因突变是影响PCI术后1年主要心血管事件的独立危险因素(P均＜0.01)。
2.PCI术后气虚血瘀组MPA、vWF、GPⅡb/Ⅲa高于非气虚血瘀组(P均<0.01),而PLT、F(1+2)和FIB两组间差异无统计学意义(P＞0.05)。
3.单因素分析显示：气虚血瘀组CYP2C19*2基因突变型(GA+AA)明显高于非气虚血瘀组(X2=26.952,P<0.01)。多因素logistic回归分析显示：以非气虚血瘀组为参照系,调整诸混杂危险因素后,CYP2C19*2基因突变型(GA+AA)的相对危险度(OR)为2.551(95%C1：1.463-4.446,P=0.001)。
四、结论
1.气虚血瘀证、血浆vWF水平、MPA70%切割点和CYP2C19*2基因突变对评价PCI预后具有重要意义。
2.在目前强化抗栓治疗的基础上,PCI术后气虚血瘀证仍存在明显的血小板活化和血管内皮损伤,但对血小板数量和凝血功能影响不大,是PCI术后1年发生主要不良心血管事件的独立危险因素。
3. CYP2C19*2基因突变可能是PCI术后气虚血瘀证的易患因素之一第二部分验证依据气虚血瘀证和CYP2C19*2基因突变联合分析指导冠脉介入术后个体化抗栓治疗药物选择的作用(前瞻性、随机、单盲、对照临床试验)
一、目的
探讨益气活血的中药复方脑心通胶囊干预PCI术后个体化抗栓治疗的疗效。
二、方法
选取行PCI成功,中医辨证属于气虚血瘀证且CYP2C19*2基因突变型(GA+AA)的冠心病患者54例,采用随机单盲对照法分为治疗组和对照组,各为27例。对照组进行术后规范抗栓治疗,治疗组在术后规范抗栓治疗的基础上加用脑心通胶囊,每次4粒,一天3次,连续使用1个月。观察治疗前、治疗后10天气虚证、血瘀证积分及远近期抗栓疗效,同时评估抗栓治疗的安全性。
三、结果
1.治疗组和对照组两组患者治疗前气虚证和血瘀证积分比较无统计学意义(P>0.05)。与治疗前比较,治疗后10天治疗组气虚证积分明显降低(P＜0.01),而对照组明显升高(P＜0.01),治疗后10天治疗组气虚证积分较对照组降低(P＜0.05)。与治疗前比较,治疗后10天两组患者血瘀证积分均明显降低(P均＜0.01),治疗后10天血瘀证积分治疗组较对照组降低(P<0.05)。
2.治疗前,两组患者PLT、MPA、血浆vWF、GPⅡb/Ⅲa、F(1+2)和FIB比较均无统计学意义(P>O.05)。与治疗前比较,治疗后10天两组患者MPA、血浆vWF、GPⅡb/Ⅲa、F(1+2)和FIB均显著降低(P均<0.01),而PLT无显著性差异(P＞0.05)。治疗后10天,治疗组MPA、血浆vWF、GPⅡb/Ⅲa、F(1+2)和FIB较对照组降低(P均<0.05),而PLT无统计学差异(P>0.05)。
3.两组患者PCI术后1个月终点事件比较发现：对照组3例发生心血管事件,其中2例发生不稳定性心绞痛,1例发生急性心肌梗死；治疗组均未发生心血管事件。根据是否发生终点事件,进行Fisher精确检验,两组差异未见统计学意义(P>0.05),有待继续扩大样本量进行观察。
4.根据PCI术后1个月的随访记录发现,治疗组和对照组在服药期间均无主要出血事件和次要出血事件发生。
四、结论
1.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊能明显降低术后10天的气虚证和血瘀证积分。
2.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊可明显抑制血小板活化,保护血管内皮细胞和改善机体凝血功能。
3.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊有降低术后1个月心血管事件发生的趋势,有待继续扩大样本量进行观察。
4.PCI术后气虚血瘀证且CYP2C19*2基因突变患者在标准抗栓治疗的基础上合用脑心通胶囊引起血小板减少和出血等药物不良反应可能性小。第三部分脑心通胶囊对人肝微粒体CYP2C19酶活力的影响
一、目的
研究脑心通胶囊对人肝微粒体中CYP2C19酶活力的影响。
二、方法
以美芬妥英为CYP2C19探针药,利用HPLC方法测定美芬妥英的代谢产物4-OH美芬妥英的浓度,研究脑心通胶囊在人肝微粒体孵化体系中对CYP2C19酶活力的影响。
三、结果
在人肝微粒体反应体系中,脑心通胶囊(0-250μg/m1)自150μg/ml开始对CYP2C19有酶促作用,且随着浓度的增加逐渐增强。
四、结论
在人肝微粒体反应体系中,脑心通胶囊(0-250μg/ml)自150μg/m1开始对CYP2C19有酶促作用,且随着浓度的增加逐渐增强。PCI术后气虚血瘀证且CYP2C19*2基因突变的患者在标准抗栓治疗的基础上合用脑心通胶囊有可能通过上述机制增强氯吡格雷抗血小板的疗效,在一定程度上改善氯吡格雷抵抗。
Part I Analysis of the clinical risk factors of Traditional Chinese Medicine (TCM) and Western Medicine affecting prognosis of percutaneous coronary intervention (PCI)
Objective
To research the clinical risk factors of TCM and Western Medicine affecting the prognosis in patients undergoing PCL and observe the effect of qi deficiency and blood stasis syndrome after PCI on antithrombotic treatment, and analyze the relationship between qi deficiency and blood stasis syndrome after PCI and polymorphisms of CYP2C19*2 gene.
Medthods
1.505 CHD patients after receiving successful PCI were adopted in this study.They were divided into with major adverse cardiac events (MACE) group and without MACE group.Multivariate logistic analysis was used to analyze the independent influencing factors of prognosis after PCI.
2.We adopted 256 CHD patients after receiving successful PCI.After 1 week of standard antithrombotic treatment, TCM syndromes were differentiated into qi-deficiency blood-stasis type and non-qi-deficiency blood-stasis type.All patients detected platelet count (PLT) n maximum platelet aggregation rate (MPA)% plasma von Willebrand factor (vWF) n platelet membrane glycoproteinsⅡb/Ⅲa (GPⅡb/Ⅲa)%prothrombin fragment 1+2 (Fl+2) and fibrinogen (FIB)
3.505 CHD patients after receiving successful PCI were adopted in this study. TCM syndromes were differentiated into qi-deficiency blood-stasis type and non-qi-deficiency blood-stasis type after 1 week of standard antithrombotic therament. All patients were genotyped for the polymorphisms of CYP2C19*2 by PCR-RFLP, and the genetic variants frequencies were compared in subjects.
Results
1.The univariate analysis and logistic regression analysis indicated that qi deficiency and blood stasis syndrome^ more than 70% in maximum platelet aggregation rate (MPA)> the level of plasma von Willebrand factor (vWF) and CYP2C19*2 gene mutation were the independent risk factors of MACE in the following 1 year after PCI (P<0.01)
2.Compared with the non-qi- deficiency blood-stasis group after PCI, the MPA、vWF and GPⅡb/Ⅲa were obviously higher in qi- deficiency blood-stasis group (P<0.01), and there were no statistical difference of PLT、F (1+2) and FIB between the two groups (P>0.05)
3.The patient genotype distribution was in Hardy-Weinberg equilibrium. Partitions ofχ2 method showed that GA+AA was higher in qi-deficiency blood-stasis group than in non-qi-deficiency blood-stasis group (χ2=26.952, P<0.01).After adjusting for common risk factors of CHD after PCI, logistic regression analysis indicated that the odds ratios (OR) of GA+AA (vs GG) genotype for qi deficiency and blood stasis syndrome was 2.551 (95%Cl:1.463-4.446, P=0.001) with the reference category of non-qi-deficiency blood-stasis syndrome.
Conclusions
1.Qi deficiency and blood stasis syndrome、70% cut-off in MPA、the level of plasma vWF and CYP2C19*2 gene mutation are very important to evaluate the prognosis for CHD patients after receiving successful PCI.
2.Qi deficiency and blood stasis syndrome after PCI affects platelete activation and ndothelial function on standard antithrombotic treatment, whereas the number of blood platelet and coagulation function may be not. Qi deficiency and blood stasis syndrome is the independent risk factor of MACE in the following 1 year after PCI.
3.The GG+AA genotype may be some heritable susceptibility to disease of qi deficiency and blood stasis syndrome after PCI. PartⅡThe directive effect of conjoint analysis qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation on individualized antithrombotic durg selection after percutaneous coronary intervention (a prospective, randomized, single-blind, controlled clinical trial)
Objective
To investigate the therapeutic effect of nao xin tong capsule on individualized antithrombotic treatment of patients undergoing PCI.
Medthods
54 CHD patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation, who had received revascularization by PCI successfully, were randomized into the treatment group and the control group, both treated with conventional western medical treatment, but the treatment group combined, respectively, with nao xin tong capsule for 1 month.The investigating items included Chinese medicine syndrome scores, short and long-term efficacy and safety assessment of antithrombotic treatment.
Results
l.The baseline between the two groups was similar. Before treatment* there was no significant difference in Chinese medicine syndrome scores (P>0.05). After treatment, qi deficiency syndrome and blood stasis syndrome scores reduced significantly in the treatment group (PO.01) and the control group showed a higher qi deficiency syndrome score and lower depressive amplitude of blood stasis syndrome score (PO.01),while significantly superior to qi deficiency syndrome and blood stasis syndrome scores in the treatment group (P<0.05).
2.Before treatment, there were no statistical difference of PLT、MPA. vWF、GPⅡb/Ⅲa, F(1+2) and FIB (P>0.05). After treatment, the indicators of MPA、vWF、GPⅡb/Ⅲa、F (1+2) and FIB went down in both groups (P<0.01), but the lowering in the control group were lesser (P0.05).The change ofPLT was insignificant between two groups (P>0.05)
3.During the period of one-month follow-up,3 MACE and zero MACE occurred in the control group and the treatment group respectively, no statistical difference was found between them (P>0.05)
4.There was no major and minor hemorrhagic complication in the treatment group and the control group.
Conclusions
1.Nao xin tong capsule may decrease qi deficiency syndrome and blood stasis syndrome scores of ten days after PCI in patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation.
2. Combination of conventional western antithrombotic treatment and nao xin tong capsule shows better efficacy in inhibiting activity of blood platelet%alleviating endothelial cell damage and improving coagulation function.
3.Along with nao xin tong capsule administration, there is a depress tendency for the occurrence of cardiovascular events during one month after PCI in patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation.
4.Combination of conventional western antithrombotic treatment and nao xin tong capsule may not increase the incidence of thrombocytopenia and bleeding complications. PartⅢEffect of nao xin tong capsule on the activity of cytochrome P2C19 (CYP2C19) in human microsome
Objective
To observe the effect of nao xin tong capsule on CYP2C19 activity in human liver microsome in vitro.
Medthod
Mephenytoin (the probe drug of CYP2C19) was incubated with or without nao xin tong capsule in human liver microsome respectively.The concentrations of mephenytoin and its metabolity (4-OH mephenytoin) were determined by HPLC, and the CYP2C19 activity was reflected by the metabolite production (4-OH mephenytoin)
Result
Compared with pre-incubation without nao xin tong capsule, the metabolite concentration of 4-OH mephenytoin had statistical difference in pre-incubation with nao xin tong capsule (150-250μg/ml)
Conclusion
Nao xin tong capsule results in an induction of CYP2C19 activity of in vitro in a dose-depentent manner. The combination of nao xin tong with clopidogrel may be reinforce the effect of antiplatelet through the above-mentioned mechanism in patients with qi deficiency and blood stasis syndrome and CYP2C19*2 gene mutation after PCI.
引文
[1]Yusuf S, Zhao F, MehtaSR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. NEnglJMed,2001,345(7): 494-502.
[2]Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet,2001,358(9281):527-533.
[3]Steinhubl SR, Berger PB, Mann JT Ⅲ, et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[4]Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction:randomised placebo-controlled trial[J]. Lancet,2005, 366 (9497):1607-1621.
[5]Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme:rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease[J]. Eur Heart J,2000,21 (24): 2033-2041.
[6]Fox KA, MehtaSR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome:the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial[J]. Circulation,2004,110 (10):1202-1208.
[7]Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy formyocardial infarction with ST-segment elevation[J].N Engl J Med, 2005,352 (12):1179-1189.
[8]Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction[J]. Circulation,2003,108:11128-11137.
[9]Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weigh heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention[J]. JAMA,2003, 289:331-342.
[10]任毅,吴瑜,张敏州,等.冠心病介入治疗围术期中医证候特征及分布规律的研究[J].中西医结合心脑血管病杂志,2010,8(6)：639-641.
[11]李健,张敏州,林晓忠,等.冠状动脉介入术对冠心病气虚血瘀证影响的临床研究[J].中西医结合心脑血管病杂志,2007,5(11)：1040-1041.
[12]陈伯钧,潘宗奇,苏学旭,等.冠心病介入治疗前后中医证型变化的研究[J].中国中西医结合杂志,2007,27(8)：689-691.
[13]李健,张敏州,陈伯钧,等.通冠胶囊对冠心病介入术后气虚血瘀证患者的影响[J].中国中西医 结合杂志,2008,28(1)：32-35.
[14]管琳,张宁宁,尹承娥.近10年来气虚血瘀型冠心病的研究概况[J].山东中医杂志,2002,21(5)：316-317.
[15]覃乔静,李荣亨.气虚血瘀证血浆NPY, ET\CGRP的改变及相关性研究[J].重庆医科大学学报,2003,28(2)：202-204.
[16]曾志立,李荣亨.气虚血瘀证患者血浆AM\ET\CGRP, NPY的变化及意义[J].中国中医基础医学杂志,2004,10(3)：22-23.
[17]荣晓凤,李荣亨,吕霞.气虚血瘀证大鼠NO. EX. TXB2.6-Keto-PGFu的变化及意义[J].中国中医基础医学杂志,2009,15(12)：914-916.
[18]赵慧辉,侯娜,王伟.冠心病气虚血瘀证的蛋白质组学特征研究[J].中国中西医结合杂志,2009,29(6)：489-492.
[19]何庆勇,王阶,张允岭,等.冠心病介入术后再狭窄危险因素及中医证候要素分析[J].北京中医药大学学报,2008,31(8)：569-572.
[20]Hulot JS, Bura A, Villard E, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood,2006, 108(7):2244-2247.
[21]Miao J, Liu R, Li Z, et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(21):2250-2251.
[22]Trenk D, Hochholzer W, FrommM F, et al. Cytochrome P4502C19681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol,2008,51(20):1925-1934.
[23]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
[24]GiustiB, Gori AM, Marcucci R, et al. Cytochrome P4502C19 loss of function polymorphism, but not CYP3A4IVS10+12GPA and P2Y12 T744C polymorphisms, is associated with response variability to dual、antiplatelet treatment in high risk vascular patients[J]. Pharmacogenet Genomics,2007,17(12)：1057-1064.
[25]Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study[J]. Lancet,2009; 373(9660):276-278.
[26]Huang MW, Wang H, Zhong WJ, et al. Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi[J]. J Chin Integr Med,2011; 9(1):38-47.
[27]Chen H, Yu GW, Sun H, et al. Comparison of adjunctive naoxintong versus clopidogrel in volunteers with the CYP2C19*2 gene mutation accompanied with qi deficiency and blood stasis constitution[J]. Evid Based Complement Alternat Med,2011:207034:1-10.
[28]陈灏珠.实用内科学[M].第12版.北京：人民卫生出版社,2005,1472-1473.
[29]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002:68-73.
[30]Mathers C, Bemard C, Iburg K, et al. Global Burden of Disease in 2002:Data Sources, Methods and Results[R]. GPE Discussion PaPer No.54. Geneva:World Health Organization,2004.
[31]Alm-Roi jer C, Stagmo M, Uden G, et al. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease [J]. Eur J Cardiovasc Nurs, 2004,3(4):321-330.
[32]杨祖福.心脏康复及其在我国的发展[J].中国康复理论与实践,2008,14(4):301-302.
[33]Singh M, Rihal CS, Gersh BJ, et al. Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary intervention:a single-institution expertience[J]. circulation,2007,115 (22):2835-2841.
[34]王师菡,王阶,何庆勇,等.冠心病介入术后中医证候要素分布规律及相关因素分析[J].世界科学技术—中医药现代化,2008,10(6)：11-15.
[35]Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis[J]. Haemophilia,2008,14:11-26.
[36]Ribes JA.Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells[J]. J Clin Invest,1987,79 (1):117-123.
[37]Cruz MA.Whitelock J, Don JF. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand factor A2 domain polypeptide as substrate[J]. Thromb Haemost, 2003,90(6):1204-1209.
[38]DenisCV, Christoph OD, Oortwi jn BD, et al. Clearance of von Willebrand factor [J]. Thromb Haemost,2008,99(2):271-278.
[39]Reininger AJ. vWF attributes-impact on thrombus formation[J]. Thromb Res,2008,122: S9-S13.
[40]MiuraS, Li CQ, CaoZ, et al. Interaction of von Willebrand factor domain Al with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion[J]. J Biol Chem,2000,275:7539-7546.
[41]Bonnefoy A, Yamamoto H, Thys C, et al. Shielding the front-strand beta 3 of the von Willebrand factor Al domain inhibits its binding to platelet glycoprotein Ibalpha[J]. Blood,2003,101:1375-1383.
[42]LipGY, Lydakis C, NuttallSL, et al. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction[J]. J Intern Med, 2000,248:316-318.
[43]Fuchs I, Frossard M, Spiel A, et al. Platelet function in patients with acute coronary syndrome(ACS) predicts recurrent ACS[J]. J Thromb Haemost,2006,4:2547-2552.
[44]Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention:insights into the STRATEGY Study[J]. J Am Coll Cardiol,2006,48:2178-2185.
[45]Blann A, Midgley H, Burrows G, et al. Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty[J]. Coron Artery Dis,1993, 4:905-910.
[46]Heper G, Murat SN, Durmaz T, et al. Prospective evaluation of von Willebrand factor release after multiple and single stenting[j]. Angiolog,2004,55:177-186.
[47]Boos CJ, Balakrishnan B, Jessani S, et al. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction[J]. Chest,2007,132(6):1920-1926.
[48]Coutts RT, Unchuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry[J]. Cell Mol Neurobiol,1999,19(3):325-354.
[49]韩运峰,冯艳萍,张树林.氯吡格雷抵抗的药物基因组学研究进展[J].中国分子心脏病学杂志,2010,(4)：249-253.
[50]Wedlund PJ.The CYP2C19 enzyme polymorphism[J]. Pharmacology,2000,61(3):174-183.
[51]Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[52]Liu XL, Wang ZJ, Yang QL, et al. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease[J]. Chin Med J,2010, 123(22):3178-3183.
[53]KangMK, Jeong YH, Yoon SE, et al. Pre-procedural platelet reactivity after clopidogrel locding in korean patients undergoing scheduled percutaneous coronary intervention[J]. J Atheroscler Thromb,2010,17(11):1122-1131.
[54]Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P4502C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel[J]. Circ J,2010,75(1):99-105.
[55]Chen H, Yan W, Wu XY. Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis [J]. Zhong guo Zhong Xi Yi Jie He Za Zhi, 2010,30(12):1245-1249.
[56]Matek LA, Przytuski J, Spiewak M, et al. Cytochrome P4502C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction[J]. Cardiology,2010,117(2):81-87.
[57]Harmsze AM, van Werkum JW, Ten Berg JM, et al.CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis:a case-control study[J]. Eur Heart J,2010,31(24): 3046-3053.
[58]Sadowitz B, Maier KG, Gahtan V. Basic science review:Statin therapy--Part I:The pleiotropic effects of statins in cardiovascular disease [J]. Vase Endovascular Surg,2010, 44(4):241-251.
[59]Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation,2003,107 (1):32-37.
[60Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet functiona flow cytometry study [J]. Eur Heart J,2003,24 (19):1744-1749.
[61]Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy[J]. Eur J Clin Invest,2005,35 (8):476-481.
[62]Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J]. Circulation,2003,108 (18):2195-2197.
[63]Gorehakova 0, von Beckerath N, Gawas M, et al. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting[J]. Eur Heart J,2004,25 (21): 1898-1902.
[64]Saw J, Steinhubl SR, BergerPB, et al. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial[J]. Circulation,2003,108 (8):921-924.
[65]Serrano Junior CV, Soeiro Ade M, Araiijo LF, et al. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation[J]. Arq Bras Cardiol,2010,95(3): 321-327.
[66]Han YL, Zhang ZL, Li Y, et al. Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting:a randomized controlled trial[J]. Zhong hua Yi Xue Za Zhi,2009,89(32):2240-2244.
[67]Blagojevic A, Delaney JA, Levesque LE, et al. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention:a cohort study[J]. Pharmacoepidemiol Drug Saf,2009,18(5):362-369.
[68]Geisler T, ZUrn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Eur Heart J,2008,29(13):1635-1643.
[67]Zhang ZJ, Marroquin 0C, Weissfeld JL, et al. Beneficial effects of statins after percutaneous coronary intervention [J]. Eur JCardiovasc Prev Rehabil,2009,16(4):445-450.
[70]Kim MC, Ahn Y, Cho KH, et al. Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction[J]. Int Heart J,2011,52(1):1-6.
[71]Shibui T, Nakagomi A, Kusama Y, et al. Impact of statin therapy on renal function and long-term prognosis in acute coronary syndrome patients with chronic kidney disease[J]. Int Heart J,2010,51(5):312-318.
[72]ISHZAKI T, HORAI Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole[J]. Alinment Pharmacol Ther,1999。13:27-36.
[73]EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS WE. Pharmacogenomics and individualized drug therapy[J]. Annu Rev Med,2006,57:119-137.
[74]GARDINER J, BEGG J. Pharmacogenetics, drug-metabolizing enzymes, and clinical pratice[J]. Pharmacol Rev,2006,58(3):521-590.
[75]Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009,180 (7):713-718.
[76]Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following cute coronary syndrome[J].JAMA, 2009,301 (9):937-944.
[77]Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101 (4):714-719.
[78]Gaspar A, Ribeiro S, Nabais S, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome [J]. Rev Port Cardiol,2010,29(10): 1511-1520.
[79]Yasu T, Ikee R, Miyasaka Y, et al. Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation:a retrospective cohort study[J]. Yakugaku Zasshi,2010,130(12):1743-1750.
[80]SimonT, Steg PG, Gilard M, et al. Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction:Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry[J]. Circulation,2011,123(5): 474-482.
[81]0rtolani P, Marino M, Marzocchi A, et al. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study[J]. J Cardiovasc Med (Hagerstown),2011 Jan 19. [Epub ahead of print].
[82]Banerjee S, Weideman RA, Weideman MW, et al. Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention[J]. Am J Cardiol,2011 Jan 17. [Epub ahead of print].
[83]Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors:a systematic review[J]. BMC Med,2010,8:81.
[84]Moran N, Kiernan A, Dunne E, et al. Monitoring modulators of platelet aggregation in a microtiter plate assay[J]. Anal Biochem 2006; 357 (7):77-84.
[85]Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting:results of the PREPARE POST-STENTING Study[J]. J Am Coll Cardiol, 2005,46(10):1820-1826.
[86]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation,2004,109(25):3171-3175.
[87]Samara WM, Bliden KP, Tantry US, et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity[J]. Thromb Res,2005,115(1-2):89-94.
[88]Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS lb study[J]. J Am Coll Cardiol,2006,48(11):2186-2191.
[89]Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention:a potential antiplatelet therapeutic target[J]. Platelets,2008,19(8):595-604.
[90]Spiel AO, Gilbert JC, Jilma B. Von Willebrand Factor in Cardiovascular Disease:Focus on Acute Coronary Syndromes[J]. Circulation,2008; 117:1449-1459.
[91]Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease[J]. Hamostaseologie,2009,29(1):32-38.
[92]吕芳芳,黄文.冠心病心绞痛不同证型与血液流变关系的探讨[J].北京中医,2004,23(6)：327-328.
[93]史培圣.冠心病气滞血瘀与气虚血瘀证型微循环比较[J].实用中西医杂志,1991,(3)：145-147.
[94]赖真,郭恕.冠心病心绞痛气虚血瘀与气滞血瘀的微循环变化[J].湖南中医学院学报,1994,(3)：441.
[95]赖世隆.血瘀证、气虚血瘀证患者TXA2、PGI2水平与微循环观察及其相关性分析[J].中国医药学报,1990,(6)：14-17.
[96]赖真,汪建红.冠心病心绞痛气虚血瘀和气滞血瘀的微循环变化[J].湖南中医学院学报,1994,14 (3)：44.
[97]刘家骏.气滞血瘀与气虚血瘀患者病理生理学的初步探讨[J].中医杂志,1991,(9)：46-47.
[98]林港祥.常见心血管病气滞血瘀、气虚血瘀证血液流变学变化[J].贵州医学,1993,(3)：185-187.
[99]孙锡印,段学忠.冠心病中医证型间血液流变性的异同及辨治对其影响[J].中医药研究,1997,(1)：121.
[100]袁肇凯,杨运高.气滞血瘀与气虚血瘀辨证微观指标的观察分析[J].中医杂志,1995,(8)：565-567.
[101]赵慧辉,陈建新,史琦,等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究[J].中国中西医结合杂志,2010,30(5)：488-492.
[102]张继东,乔云,武传龙,等.冠心病患者胰岛素抵抗与中医辨证分型及纤溶系统活性的相关性研究[J].中国中西医结合杂志,2004,24(5)：408-410.
[103]张宁宁,尹承娥,吕芳芳,等.气滞血瘀、气虚血瘀心绞痛患者心率变异性与心肌缺血指数相关性探讨[J].山东中医药大学学报,2003,27(2)：123-124.
[104]谷旭放.冠心病心绞痛气虚血瘀证与气滞血瘀证平板运动试验结果对照分析[J].中国全科医学,2010,13(6A)：1808-1812.
[105]杨东辉,孙博,郭艳艳.冠心病患者中医证型与颈动脉内膜-中层厚度及踝臂指数的相关性研究[J].云南中医中药杂志,2009,30(9)：5-6.
[106]朱萱萱,王广基,达庆国,等.冠心病中医证型与冠状动脉造影的相关性研究[J].中华中医药学刊,2010,28(8)：1579-1581.
[107]贾玉柱,沈盛晖,祁克信,等.冠心病中医证候与16层螺旋CT冠状动脉造影的相关性分析[J].中国中医急症,2010,19(10)：1703-1704.
[108]朱翠玲,闫奎坡,朱明军,等.冠心病中医证型与冠状动脉病变的相关性研究[J].中国中药杂志,2009,34(24)：3289-3291.
[109]胡元会,吴林,周次清.经皮冠状动脉介入治疗后再狭窄的中医病机治法钩玄[J].中国中医基础医学杂志,2003,9(2)：14-16.
[110]潘毅.心气虚证计量诊断再探[J].广州中医学院学报,1995,12(1)：10—13.
[111]陈可冀.活血化瘀研究与临床[M].北京：北京医科大学中国协和医科大学联合出版社,1993：3-7.
[112]Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase[J]. J Am Coll Cardiol,1988,11 (1):1-11.
[113]0ng AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal sirolrmus or paclitaxel stent implantation[J]. J Am Coll Cardiol,2005,45(6):947-953.
[114]Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents[J]. JAMA,2005,293(17):2126-2130.
[115]Kereiakes DJ, Choo JK, Young JJ, et al. Thrombosis and drug-eluting stents:a critical appraisal[J]. Rev Cardiovasc Med,2004;5(1):9-15.
[116]Fenwei W, Stouffer GA, Waxman S, et al. Late coronary stent thrombosis:Early vs late stent thrombosis in the stent era. Commentary[J]. Catheterization and Cardiovascular Interventions,2002,55(2):142-149.
[117]Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents[J]. N Engl J Med,2007,356(10):1020-1029.
[118]陈立娟,马根山,冯毅,等.紫杉醇药物涂层支架治疗左前降支病变临床研究[J].东南大学学报：医学版,2006,25(6)：423-426.
[119]Tsimikas S. Drug-eluting stents and late adverse clinical outeomes lessons learned, lessons awaited[J].J Am Coll Cardiol,2006,47(10):2112-2125.
[120]Rodriguez AE, Mieres J, Fernandez-Pereira C, et al.Coronaty stent. Thrombosis in the current drug-eluting stent era:insights from the ERACI HI trial[J].J Am Coll Cardiol, 2006,47(1):205-207.
[121]Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease[J].J Am Coll Cardiol,2007,50(19):1822-1834.
[122]The EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa in high risk coronary angioplasty[J].N Engl J Med,1994,330:956-961.
[123]EPILOG Investigators. Platelet glycoprotein Ⅱb/Ⅲa blockade with abciximab with low dose heparin during percutaneous coronary revascularization[J].N Engl J Med,1997,336: 1689-1696.
[124]EPISTENT Investigators. Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein Ⅱb/Ⅲa blockade[J]. Lancet,1998,352:87-92.
[125]CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina:the CAPTURE study[J]. Lancet, 1997,349:1429-1435.
[126]IMPACT Ⅱ Investigators. Randomized placebo controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT Ⅱ [J]. Lancet, 1997,349:1422-1428.
[127]The RESTORE Investigators. Effect of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction[J]. Circulation,1997,96:1445-1453.
[128]Christersson C, Oldgen J, Bylock A, et al. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events:Observations from the ESTEEM trial[J]. Eur Heart J,2007; 28 (6):692-698.
[129]Vischetti M, Zito F, Donati MB, et al. Analysis of gene enviorment irrteraction in coronary heart disease:fibrinogen polymorphisms as an example [J]. Ital Heart J,2002; 3 (1):182-231.
[130]Coppola G, Rizzo M, Abrignami MG, et al. Fibrinogen as a predictor of mortality after acute myocardial infarction:a forty-two month follow-up study[J]. Ital Heart J,2005; 6 (4):315-322.
[131]赵步长,伍海勤,赵涛主编.脑心同治—心脑血管疾病防治进展[M].北京：人民卫生出版社,2006：298-334.
[132]张艳玲,莫炜,王龙生,等.重组双功能水蛭素抗凝防栓作用的实验研究[J].中华手外科杂志,2006,22(2)：106-108.
[133]顾立新.脑心通胶囊治疗冠心病心绞痛气虚血瘀证的疗效观察[J].中西医结合心脑血管病杂志,2006；4(10)：925-926.
[134]王凤科.步长脑心通胶囊对冠心病患者血粘度与内皮细胞功能的影响[J].山东医药,2007;47(28)：70-71.
[135]陈达开,张怀勤,张建华.脑心通胶囊对阿司匹林抗血小板治疗的影响[J].中医杂志,2008;49(7)：605-607.
[136]张加力,杜立树,平龙玉,等.脑心通胶囊对87例冠心病患者血清CPR的影响[J].中医杂志,2006;47(6)：472-473.
[137]任丁,吴云虎,黄建民,等.脑心通胶囊对血管支架成型术后再狭窄预防作用的研究[J].中西医结合心脑血管病杂志,2009；7(3)：361-362.
[138]吴发宝,陈希元.黄芪药理研究综述[J].中药材,2004,23(7)：233-234.
[139]夏泉,张平,李邵平,等.当归的药理作用研究进展.时珍国医国药[J],2004,15(3)：16-18.
[140]胡芬,向继洲.中药治疗血小板性紫癜的药理作用.医药导报[J],2005,24(6)：480-482.
[141]陈东辉,罗霞,余梦瑶,等.鸡血藤煎剂对小鼠骨髓细胞增殖的影响[J].中国中药杂志,2004,29(4)：352—355.
[142]Vol Bohr C, Groth CG, Jansson H, et al. Drug metabolism in human liver in vitro:Establishment of a human liver bank[J].Clin Pharmacol Ther,1980,27:711-723.
[143]Bray ton CF, Dimethyl sulfoxide (DMSO):areview[J]. Cornell Vet,1986,76 (1):61-90.
[144]Glockner R, Steinmetzer P, Drobner C. Application of cryopreserved precision-cut liver slices in pharmacotoxicology-principles, literature data and own investigations with special reference to CYPlAl-mRNA induction[J]. Exp Toxicol Pathol,1998,50(4-6):440-449.
[145]Hengstler JG, Utesch D, Steinberg P, et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction[J]. Durg Metab Rev,2000,32(1):81-118.
[146]李焕德,李坤艳.药物代谢性相互作用体外研究的重要性[J].中南药学,2005,3(3)：179-181.
[147]王汝龙.三哇类抗深部真菌药的临床药学进展[J].临床药物治疗杂志,2007,5(1):1-7.
[1]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002:68-73.
[2]全国冠心病辨证论治研究座谈会.冠心病中医辨证试行标准[J].中医杂志,1980,(8)：46.
[3]中西医结合心血管学会.冠心病的中医辨证标准[J].中西医结合杂志,1991,11(5)：257.
[4]孙春霞,颜乾麟,黄书慧,等.1001例冠心病介入术后患者中医证候调查[J].中医杂志,2010,51(9)：827-829.
[5]任毅,吴瑜,张敏州,等.冠心病介入治疗围术期中医证候特征及分布规律的研究[J].中西医结合心脑血管病杂志,2010,8(6)：639-641.
[6]李健,张敏州,林晓忠,等.冠状动脉介入术对冠心病气虚血瘀证影响的临床研究[J].中西医结合心脑血管病杂志,2007,5(11)：1040-1041.
[7]陈伯钧,潘宗奇,苏学旭,等.冠心病介入治疗前后中医证型变化的研究[J].中国中西医结合杂志,2007,27(8)：689-691.
[8]王师菡,王阶,何庆勇,等.冠心病介入术后中医证候要素分布规律及相关因素分析[J].世界科学技术—中医药现代化,2008,10(6)：11-15.
[9]何庆勇,王阶.基于聚类分析的冠心病介入术后中医证候分类及诊断[J].中医杂志,2008,49(10)：918-921.
[10]李世林,程伟,王鹏.冠心病药物洗脱支架植入患者介入前后中医证型变化的研究[J].中西医结合心脑血管病杂志,2010,8(2)：151-152.
[11]严卉,胡晓晟,陈君柱,等.血浆同型半胱氨酸和冠状动脉粥样硬化严重程度与中医证型的关系[J].中国中西医结合杂志,2002,22(11)：813-815.
[12]方显明,唐耀平,郑德俊.冠心病血浆同型半胱氨酸与中医证型的相关性[J].中医杂志,2005,46(10)：775-776.
[13]蒋华,赵永东.冠心病患者血浆同型半胱氨酸水平与中医辨证分型的相关性研究[J].新疆中医药,2008,26(4)：23-25.
[14]刘敏,张培影.不稳定性心绞痛中医证型与Hcy、hs-CRP的关系[J].浙江中西医结合杂志,2009,19(7)：406-407.
[15]尤卫平,石磊,韦爱欢,等.冠心病中医辨证分型与内皮损伤、炎症反应及血小板活化的相关性研究[J].广州中医药大学学报,2008,25(5)：457-460.
[16]陈玉婷,胡娟娟,余姚,等.冠心病痰瘀辨证分型与相关生化指标关系探讨[J].浙江中西医结合杂志,2005,15(3)：144-146.
[17]林超,郭进建,林青,等.高敏C反应蛋白与不稳定型心绞痛中医证型相关性研究[J].中国中医急症,2007,16(10)：1221-1223.
[18]商秀洋,石洁.冠心病中医辨证与血清高敏c反应蛋白的关系研究[J].现代中西医结合杂志,2008,17(6)：818-820.
[19]郑峰,曲丹,徐浩,等.冠心病稳定期患者中医辨证与超敏c反应蛋白相关性研究[J].中国中西医结合杂志,2009,29(6)：485-488.
[20]李创鹏,刘培中,刘克锋,等.冠心病辨证分型与心血管危险因素相关性研究[J].新中医,2010,42(9)：35-37.
[21]朱翠玲,何卫士,朱明军,等.FIB与冠心病中医证型及体质量的相关性研究[J].中医学报,2010,25(151)：1151-1153.
[22]龙卫平,陈剑,何汉康,等.女性冠心病患者中医证型及冠状动脉造影特点的研究[J].上海中医药大学学报,2010,24(4)：45-47.
[23]王子宽,柳荫,李波,等.冠心病危险因素与中医证型相关性分析[J].陕西中医学院学报,2008,31(6)：6-8.
[24]于顾然,贺燕勤,郭云庚,等.冠心病中医证型与胰岛素抵抗、脂质及红细胞膜ATP酶关系的临床研究[J].中医杂志,2000,41(2)：111-112.
[25]王洪泉.冠心病血脂异常与中医辨证关系研究[J].中国社区医生,2010,12(248)：135.
[26]魏丹霞,刘明,庞永诚,等.冠心病患者血脂水平与中医辨证分型的相关研究[J].中国中医急症,2010,19(3)：441-442.
[27]褚福永,王阶,姚魁武,等.冠心病不稳定型心绞痛中医辨证分型与血脂及冠脉造影结果的相关性研究[J].北京中医药,2009,28(12)：918-921.
[28]刘明,魏丹霞,陈奇刚,等.急性心肌梗死患者血脂水平变化与中医辨证分型的临床研究[J].中国中西医结合急救杂志,2001,8(1)：29-30.
[29]其其格,王伟,毕力夫,等.冠心病血瘀证与血脂血尿酸关系的探讨[J].辽宁中医杂志,2008,35(12)：1826-1827.
[30]唐巍,遇红,李江涛,等.冠心病患者血中胰岛素、胰高血糖素与中医证候类型关系的研究[J].中国中医基础医学杂志,2002,8(9)：53-55.
[31]陈晓虎,徐顺娟.冠心病(胸痹)胰岛素抵抗与中医辨证分型关系的临床研究[J].南京中医药大学学报,2006,22(5)：296-298.
[32]张继东,乔云,武传龙,等.冠心病患者胰岛素抵抗与中医辨证分型及纤溶系统活性的相关性研究[J].中国中西医结合杂志,2004,24(5)：408-410.
[33]王阶,李霁,杨戈.外周血白细胞与冠状动脉狭窄程度及冠心病中医证型之间的关系[J].中国中西医结合杂志,2010,30(2)：130-132.
[34]尹克春,罗翌,曾星.冠心病血瘀证病人血白细胞CD11b/CD18表达的研究[J].中西医结合心脑血管病杂志,2003,1(7)：381-383.
[35]贺劲.血液流变性改变与冠心病中医证型关系研究[J].中国中医急症,2008,17(10)：1401-1403.
[36]曹雪明,张泉,郑重,等.冠心病中医证型与血液流变学相关性探讨[J].中国中医急症,2006,15(11)：1242-1243.
[37]李越华,肖沪生.冠心病中医辨证分型与心功能及血液流变学之间关系的研究[J].辽宁中医杂志,2004,31(12)：998-999.
[38]丘瑞香,罗致强,宋雅宜,等.冠心病血瘀证血液理化特性与中医证型相关性研究[J].中医杂志,2002,43(5)：378-390.
[39]张冬梅,陈建鸿,祝梅华.冠心病中医辨证与血液流变学的关系[J].现代福州总医院学报,1999,6(2)：42-43.
[40]吕芳芳,黄文.冠心病心绞痛不同证型与血液流变关系的探讨[J].北京中医,2004,23(6)：327-328.
[41]赖真,汪建红.冠心病心绞痛气虚血瘀和气滞血瘀的微循环变化[J].湖南中医学院学报,1994,14 (3)：44.
[42]李进兵,冯靖禧,陈伯钧,等.冠心病稳定型心绞痛中医证型与血管内皮功能相关性研究[J].世界中西医结合杂志,2010,5(8)：688-691.
[43]陈昕琳,顼志兵,顾仁樾.vWF、Ps.水平与冠心病中医证型相关性的临床研究[J].湖北中医杂志,2007,29(8)：11-12.
[44]梁知,顼志兵,顾仁樾.冠心病中医证型与P-选择素相关性的临床研究[J].辽宁中医杂志,2006,33(12)：1595-1596.
[45]梁知,项志兵,顾仁樾.血管性血友病因子、血栓素B2及6-酮-前列环素与冠心病中医证型相关性的临床研究[J].上海中医药杂志,2006,40(6)：13-14.
[46]徐采云,邢之华,刘卫平,等.冠心病不同中医证型与血浆纤维蛋白原的相关性研究[J].中医康复,2010,25(3)：190-192.
[47]王娟,安冬青.冠心病秽浊痰阻证与纤维蛋白原和血栓前体蛋白的关系探讨[J].云南中医中药杂志,2010,31(4)：18-19.
[48]孙红艳,安冬青,宋刚,等.冠心病秽浊痰阻证与血浆t-PA、PAI-1及Fib的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4)：389-391.
[49]吕中,施赛珠,祝光礼.冠心病患者单核细胞凝血／纤溶活性改变与中医证型关系[J].中国中医基础医学杂志,2001,7(3)：59-61.
[50]莫鸿辉,黄衍寿,洪永敦,等.黏附分子-1血清水平及基因多态性与冠心病痰瘀证候关系研究[J].新中医,2009,41(11)：25-28.
[51]王强,程胜军.冠心病心绞痛中医证型与IL-18、hs-CRP的相关性探讨[J].广西中医药,2008,31(4)：14-15.
[52]雷瑗琳,乔会侠,赵明君.冠心病合并肥胖症患者血清瘦素水平与中医证候的相关性研究[J].陕西中医,2008,29(6)：645-646.
[53]李成林,王庆高,朱智德.冠心病心绞痛中医证型与脑钠肽、C-反应蛋白和肌钙蛋白相关性研究[J].新中医,2008,40(7)：32-33.
[54]林桂永,阮威君.急性冠脉综合征痰瘀证与炎症关系的临床研究[J].中国民康医学,2008,20(9)：872-875.
[55]李俊,王大伟,严夏,等.冠心病不稳定型心绞痛中医证候与C-反应蛋白和基质金属蛋白酶-9关系的研究[J].辽宁中医药大学学报,2008,10(2)：102-103.
[56]杨徐杭,汶医宁,党琳,等.冠心病中医辨证与血清E-选择素、细胞间粘附分子-1的关系研究[J].四川中医,2008,26(1)：61-62.
[57]李静,张继东,刘同涛.血清胆红素与冠脉病变程度、血脂及冠心病中医证型关系[J].南京中医药大学学报,2006,22(2)：77-79.
[58]刘剑刚,许勇钢,苏庆民.冠心病血瘀证的T细胞亚群、血脂和血液流变性改变及其相互关系[J].中国微循环,1999,3(4)：254.
[59]涂伟钦,张月菊.冠心病患者微量元素及自由基与中医辨证关系研究[J].天津中医药,2006,23(1)：37-38.
[60]莫鸿辉,潘佩光,黄衍寿,等.冠心病痰瘀证候与载脂蛋白E基因多态性相关性的研究[J].广州中医药大学学报,2010,27(4)：418-423.
[61]洪永敦,莫鸿辉,朱会英,等.ApoE血清水平及基因多态性与冠心病痰瘀证候关系的研究[J].新中医,2009,41(2)：42-44.
[62]赵冰,郭宏敏.老年冠心病痰瘀证ApoE基因多态性分布特点研究[J].山西中医,2008,24(10)：37-39.
[63]韩旭,李七一,赖仁胜,等.ApoE基因多态性与冠状动脉粥样硬化性心脏病中医证型的相关性研究[J].中华中医药学刊,2009,27(11)：2323-2330.
[64]欧阳涛,宋剑南,李林,等.冠心病痰瘀证候与载脂蛋白E第一内含子增强子基因多态性关系的 研究[J].中国中医基础医学杂志,2005,11(6)：414-417.
[65]吴依芬,周迎春,王刚,等.冠心病中医证型与GNB3基因C825T多态性的关联性分析[J].四川中医,2006,24(10)：23-25.
[66]吴依芬,周迎春,张学森.中国汉族男性冠状动脉粥样硬化性心脏病患者中医证型与ABCA1基因R219K多态性的关联性[J].中国临床康复,2006,10(7)：7-9.
[67]黄献平,袁肇凯,毛以林,等.冠心病血瘀证凝血因子Ⅶ基因多态性的检测分析[J].中西医结合心脑血管病杂志,2006,4(2)：97-99.
[68]毛以林,袁肇凯,黄献平,等.冠心病血瘀证与血管紧张素转换酶基因多态性的相关性研究[J].中国中西医结合杂志,2004,24(9)：776-780.
[69]朱会英.冠心病痰瘀证与C-反应蛋白、E-选择素水平及其基因多态性关系研究[J].广州：广州中医药大学,2007.
[70]王东生,袁肇凯.冠心病痰瘀辨证与外周血单核细胞PDGF-A mRNA表达的关系[J].安徽中医学院学报,2003,22(2)：14-16.
[71]王阶,杨保林,姜燕.冠心病血瘀证相关基因研究[J].世界科学技术-中医药现代化,2005,7(1)：16-19.
[72]李炜弘,王米渠,王刚,等.冠心病心阳虚证相关差异表达基因分析[J].现代中西医结合杂志,2004,13(24)：3219-3222.
[73]朱新星,张进军.冠心病不同虚证与血气分析关系的研究[J].中国医学工程,2005,13(2)：207-208.
[74]褚田明,顾仁樾.冠心病阳虚证与心功能减退关系的研究——附262例临床资料[J].江苏中医药,2007,39(6)：17-18.
[75]姜洪茹,郭勇.超声评价左心室收缩功能与冠心病实证者辨证分型关系初探[J].中国医药导报,2007,4(14)：20-21.
[76]刘辛光.冠心病辨证分型与血液动力学流变学变化关系探析[J].辽宁中医杂志,2005,46(6)：991.
[77]陈伯钧,张文清,张敏州.冠心病中医分型与心律失常及心功能关系分析[J].现代中西医结合杂志,2000,9(19)：1857-1858.
[78]刘雪梅,蒋红红,陈征宇,等.冠心病中医辨证分型与心电图关系的相关研究[J].河南中医学院学报,2009,24(143)：67-68.
[79]李方洁,白净,杨新春,等.心率变异性非线性特征与冠心病虚实证候相关性研究[J].辽宁中医杂志,2008,35(9)：1306-1308.
[80]宋娅萍.冠心病QT、JT离散度与中医证型关系分析[J].中国中医急症,2008,17(8)：1097-1099.
[81]谢慧文,张伟,孙敬和.冠心病中医证型与心电图QRS波群离散度的关系[J].上海中医药大学学报,2007,21(2)：31-33.
[82]杜廷海,朱明军,程江涛,等.冠心病中医证型与心电信息相关性的初步观察[J].中西医结合心脑血管病杂志,2006,4(1)：8-9.
[83]丁邦晗,杨敏,周珂,等.胸痹心痛患者心电图改变与中医证型的关系[J].中国中西医结合急 救杂志,2008,15(1)：31-33.
[84]王润桃,王硕仁,邢雁伟.血瘀证与心电图异常的关系[J].中医杂志,2006,46(6)：418.
[85]张宁宁,尹承娥,吕芳芳,等.气滞血瘀、气虚血瘀心绞痛患者心率变异性与心肌缺血指数相关性探讨[J].山东中医药大学学报,2003,27(2)：123-124.
[86]王玉燕,杜武勋,魏营,等.冠心病不同证型与颈动脉内-中膜厚度关系的研究[J].山西中医,2009,25(2)：34-36.
[87]杨东辉,孙博,郭艳艳.冠心病患者中医证型与颈动脉内膜-中层厚度及踝臂指数的相关性研究[J].云南中医中药杂志,2009,30(9)：5-6.
[88]程康林,覃勇,陈仁山,等.痰浊型冠心病患者痰浊证与颈动脉斑块的相关性分析[J].新中医,2006,38(8)：20-21.
[89]贾玉柱,沈盛晖,祁克信,等.冠心病中医证候与16层螺旋CT冠状动脉造影的相关性分析[J].中国中医急症,2010,19(10)：1703-1704.
[90]沈培红,毛威,叶武,等.64层螺旋CT冠脉成像与胸痹证型的相关性研究[J].中华中医药学刊,2010,28(6)：1224-1226.
[91]潘涛,宫剑滨,郭华,等.冠心病中医证型与冠状动脉双源CT成像相关性研究[J].中西医结合心脑血管病杂志,2007,5(10)：914-916.
[92]谷旭放.冠心病心绞痛气虚血瘀证与气滞血瘀证平板运动试验结果对照分析[J].中国全科医学,2010,13(6A)：1808-1812.
[93]张玉辉,毛静远,王占武,等.冠心病心绞痛气阴两虚及兼痰瘀证平板运动试验结果对照分析[J].中国中西医结合杂志,2005,25(4)：315-319.
[94]杜健鹏,史大卓,李田昌,等.冠心病稳定期血瘀证与冠状动脉病变特点的相关性[J].中西医结合学报,2010,8(9)：848-852.
[95]朱萱萱,王广基,达庆国,等.冠心病中医证型与冠状动脉造影的相关性研究[J].中华中医药学刊,2010,28(8)：1579-1581.
[96]任毅,陈可冀,张敏州,等.405例冠心病患者冠状动脉造影结果与中医证型的相关性[J].中医杂志,2010,51(8)：725-728.
[97]王振裕,时亮,陈嘉兴,等.冠心病患者中医证候与冠状动脉造影相关性研究[J].中华中医药杂志,2009,24(9)：1194-1197.
[98]杨阳,李方洁,杨新春,等.冠心病中医证候及脾虚痰浊证与冠脉病变的关系对比观察[J].中华中医药杂志,2010,25(3)：352-354.
[99]朱翠玲,闫奎坡,朱明军,等.冠心病中医证型与冠状动脉病变的相关性研究[J].中国中药杂志,2009,34(24)：3289-3291.
[100]邢雁伟,李尊,王阶,等.冠脉病变特征和中医证候要素关系的研究[J].辽宁中医杂志,2008,35(1)：36-38.
[101]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的血浆代谢组学研究[J].新中医,2010,42(6)：12-14.
[102]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国 中医基础医学杂志,2010,16(2)：126-128.
[103]华何与,贾钰华,张红栓,等.冠心病心绞痛三种血瘀证的血浆代谢组学研究[J].热带医学杂志,2010,10(3)：258-260.
[104]王广基,阿基业,严蓓,等.代谢组学研究冠心病中医分型的体内物质基础[J].世界科学技术—中医药现代化,2009,16(8)：127-133.
[105]赵慧辉,陈建新,史琦,等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究[J].中国中西医结合杂志,2010,30(5)：488-492.
[106]王阶,汤艳莉,何庆勇.冠心病心绞痛患者证候要素与生存质量的相关性[J].中医杂志,2010,51(2)：154-163.
[107]金明华,秦鉴,吴伟康,等.513例冠心病患者心绞痛类型与中医证型关系的研究[J].中医杂志,2009,50：185-186.
[108]杨俊华,杨国靖,刘茹.冠心病患者A型性格与情绪障碍及中医辨证分型关系的探讨[J].中国中医药信息杂志,2009,16(8)：23-25.
[109]西原辰一,史载祥,酒谷薰.应用可视光组织氧监测评价冠心病血瘀证舌诊的研究[J].中西医结合心血管病杂志,2009,7(11)：1274-1276.
[110]史载祥,武泽民,许树强.冠心病血瘀证病人舌分光定量以及舌表浅血流量观察[J].中西医结合杂志,1991,11(7)：407.
[111]李绍芝.心气虚病之脉图参数的初步观测[J].中医杂志,1987,28(1)：9.
[1]Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med,2001,345(7): 494-502.
[2]Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet,2001,358(9281):527-533.
[3]Steinhubl SR, Berger PB, Mann JT Ⅲ, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[4]Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction:randomised placebo-controlled trial[J]. Lancet,2005, 366 (9497):1607-1621.
[5]Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme:rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease[J]. Eur Heart J,2000,21 (24): 2033-2041.
[6]Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome:the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial[J]. Circulation,2004,110 (10):1202-1208.
[7]Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy formyocardial infarction with ST-segment elevation[J].N Engl J Med, 2005,352 (12):1179-1189.
[8]Kazui M, Nishiya Y, Ishizuka T, et al. Identif ication of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos,2010,38(1):92-99.
[9]Wiviott SD, Antman EM. Clopidogrel resistance:a new chapter in a fast-moving story [J]. Circulation,2004,109:3064-3067.
[10]Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel:a review of the evidence[J]. J Am Coll Cardiol.2005,45(8):1157-1164.
[11]Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost,2003,89:783-787.
[12]Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J]. Circulation,2004,109: 166-171.
[13]Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation,2003,107:2908-2913.
[14]Wenaweser P, Dorffler Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy [J]. J Am Coll Cardiol,2005,745 (11):1748-1752.
[15]Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNowHP2Y12 cartridge for monitoring platelet inhibition with clopidogrel[J]. Methods Find Exp Clin Pharmacol,2006, 28 (5):315-322.
[16]Laurent B, Laurence CJ. Adjusted clopidogrel loading doses according to vasodilator stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel res i stance [J]. Am Coll Cardiol,2008, 51(14):1404-1411.
[17]Schumann A, Wiesenburg A, Bucha E, et al. Platelet Adhesion Assay (PADA), a new quantitative test for assessment of platelet function and the apeutic drug monitoring of GPⅡb/Ⅲa and ADP receptor antagonists [J]. Hamostaseologie,2004,24(3):211-216.
[18]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J,2004,25(6):476-483.
[19]Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption[J]. Clin Pharm acol Ther,2006,80(5):486-501.
[20]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
[21]Coutts RT, Unchuk LJ. Polymorphic cytochromes p450 and drugs used in psychiatry[J]. Cell Mol Neurobiol,1999,19(3):325-354.
[22]Wedlund PJ. The CYP2C19 enzyme polymorphism[J]. Pharm acology,2000,61(3):174-183.
[23]Hulot JS, Bura A, Villard E, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood,2006, 108(7):2244-2247.
[24]Miao J, Liu R, Li Z. Cytochrome P-450 polymorphisms and response to clopidogrel [J].N Engl J Med,2009,360(21):2250-2251.
[25]Trenk D, Hochholzer W, FrommM F, et al. Cytochrome P4502C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol,2008,51(20):1925-1934.
[26]Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss of function polymorphism, but not CYP3A4IVS10+12GPA and P2Y12 T744C polymorphisms, is associated with response variability to dual、antiplatelet treatment in high risk vascular patients[J]. Pharmacogenet Genomics,2007,17(12):1057-1064.
[27]Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study[J]. Lancet,2009, 373(9660):276-278.
[28]Angiolillo DJ, Ferna' ndez-Ortiz A, Bernardo E, et al. Contributio of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel[J]. A rterioscler Thromb Vase Biol,2006,26(8):1895-1900.
[29]Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel[J]. CMAJ,2006,174(12): 1715-1722.
[30]Smith SM, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy[J]. Platelets,2006,17(4):250-258.
[31]Brandt JT, Close SL, IturriaSJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J]. J Thromb Haem ost,2007,5(12):2429-2436.
[32]Cavallari U, Trabetti E, Malerba G, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease[J]. BMC M ed Genet,2007,8: 59.
[33]Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2 haplotype is associated with peripheral arterial disease:a case-control study[J]. Circulation,2003,108(24):2971-2973.
[34]Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease[J]. Stroke,2005,36(7):1394-1399.
[35]Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600mg loading dose of clopidogrel in 597 patients with non-ST segment elevation acute coronary syndrome[J]. Thromb Res,2007,120(6):893-899.
[36]Malek LA, Bartlomiej MD, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel [J]. Circulation, 2008,72(7):1165-1169.
[37]Schettert IT, Pereira AC, Lopes NH, et al. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease [J]. Thromb Res,2006,118(6): 679-683.
[38]Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation,2003,107 (1):32-37.
[39]Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet functiona flow cytometry study [J]. Ear Heart J,2003,24 (19):1744-1749.
[40]Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy[J]. Eur J Clin Invest,2005,35 (8):476-481.
[41]Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J]. Circulation,2003,108 (18):2195-2197.
[42]Gorehakova 0, von Beckerath N, Gawas M, et al. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting[J]. Eur Heart J,2004,25 (21): 1898-1902.
[43]Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial[J]. Circulation,2003,108 (8):921-924.
[44]Serrano Junior CV, Soeiro Ade M, Araujo LF, et al. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation[J]. Arq Bras Cardiol,2010,95(3): 321-327.
[45]Han YL, Zhang ZL, Li Y, et al. Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting:a randomized controlled trial[J]. Zhong hua Yi Xue Za Zhi,2009,89(32):2240-2244.
[46]Blagojevic A, Delaney JA, Levesque LE, et al. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention:a cohort study[J]. Pharmacoepidemiol Drug Saf,2009,18(5):362-369.
[47]Shen J, Zhang RY, Zhang Qet al. Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina[J]. Zhong Hua Xin Xue Guan Bing Za Zhi,2008,36(9):807-811.
[48]Geisler T, Zttrn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Eur Heart J,2008,29(13):1635-1643.
[49]董红娟,刘治军,傅得兴.他汀药物对氯毗格雷抗血小板活性影响的研究进展[J].中国药师,2009,12(3)：324-327.
[50]ISHZAKI T.HORAI Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole[J]. Alinment Pharmacol Ther,1999,13:27-36.
[51]EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS WE. Pharmacogenomics and individualized drug therapy[J]. Annu Rev Med,2006,57:119-137.
[52]GARDINER J, BEGG J. Pharmacogenetics, drug-metabolizing enzymes, and clinical pratice[J]. Pharmacol Rev,2006,58(3):521-590.
[53]Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009,180 (7):713-718.
[54]Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA, 2009,301 (9):937-944.
[55]Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101 (4):714-719.
[56]Havranek EP, Weinberger J. Concomitant use of angiotensin converting enzyme(ACE) inhibitors and antiplatelet therapies:clopidogrel versus aspirin [J]. J Hypertens,1999, 17:S57.
[57]De Miguel A, Ibanez B, Badimon JJ, et al. Clinical implications of clopidogrel resistance[J]. Thromb Haemost,2008,100(2):196-203.
[58]Serebruany VL. The "clopidogrel resistance" trap[J]. Am J Cardiol,2007,100(6): 1044-1046.
[59]Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina [J]. Catheter Cardiovasc Interv, 2003,59 (1):21-25.
[60]谭丽玲,贾三庆,王明生,等.急性冠脉综合征患者氯吡格雷抵抗的影响因素[J].中国心血管病研究杂志,2006,4(9)：680.
[61]SluggPH, Much DR, Smith WB, et al. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel[J]. J Clin Pharmacol,2000,40(4):396-401.
[62]Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose[J].Thromb haemost,2004,92:311-316.
[63]Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel [J]. J Intern Med,2002,252 (3)：233-238.
[64]Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance:role of body mass and concomitant medications[J]. Int J Cardiol,2007,120 (2):188-192.
[65]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation,2004,109 (25):3171-3175.
[66]Lev El, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J]. J Am Coll Cardiol,2006,47 (1):27-33.
[67]Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetesmellitus and coronary artery disease[J]. J Am Coll Cardiol,2007,50(16):1541-1547.
[68]Westerbacka J, Yki-jarvinen H, Turpeinen A, et al. Inhibition of platelet collagen interaction:an in vivo action of insulin abolished by insulin resistance in obesity[J]. Arterioscler Thromb Vase Biol,2002,22 (2):167-172.
[69]Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors inmedically treated patients with coronary disease [J]. Int J Obes (Lond),2008,32(6):967-974.
[70]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J,2004,25 (6):476-483.
[71]Pozgajovd M, Sachs UJ, Hein L, et al. Reduced thrombus stability in mice lacking the alpha2A-adrenergic receptor[J]. Blood,2006,108(2):510-514.
[72]Beres BJ, Toth-Zsdmboki E, Vargovd K, et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy[J]. Thromb Haemost,2008,100(5):829-838.
[73]Maayani S, Schwarz T, Craddock-Royal B, et al. Activation of the alpha (2A)-adrenoceptormediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro[J]. Platelets,2001,12(6):359-375.
[74]Dziewierz A, Dudek D, Heba G, et al. Interindividual variability in response to clopidogel in patients with coronary artery disease[J]. KardiolPol,2005,62(2):108-117.
[75]Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptif ibatide to arrest the reactivity of platelet:results of the Clopidogrel Loading With Eptif ibatide to Arrest the Reactivity of Platelet (CLEAR PLATELETS)study[J]. Circulation,2005,111:1153-1159.
[76]von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-,600-, and 900-mg loading doses of clopidogrel:results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen:Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial[J]. Circulation,2005,112(19): 2946-2950.
[77]Yong G, Rankin J, Ferguson L, et al. Randomized trial comparing 600-with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention:results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL)Trial[J]. Am Heart J,2009,157(1):60el-69el.
[78]张建维,贾三庆,曹树军,等.不同负荷量的氯吡格雷对急性冠脉综合征患者血小板聚集功能及氯吡格雷抵抗发生率的影响[J].实用医学杂志,2007,23(1)：60-69.
[79]Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300 and 450mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation[J]. Am Heart J,2002,143(1):118-123.
[80]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting:effects on drug response and interindividual variability[J]. Eur Heart J,2004,25:1903-1910.
[81]Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting [J]. J Am Coll Cardiol,2006,48: 1339-1345.
[82]Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel:the PRINC(Plavix Response in Coronary Intervention)trial[J]. JACC Cardiovasc Interv,2008,1(6):612-619.
[83]Sprigg N, Gray LJ, England T, et al. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility[J]. PLoS ONE,2008,3(8):e2852.
[84]Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome [J]. JAMA,2008,299(5): 532-539.
[85]Danzi GB, Capuano C, SesanaM, et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein Ⅱb/Ⅲa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention[J]. Am J Cardiol,2006,97(4): 489-493.
[86]De Servi S, Mariani M, Vandoni P, et al. Use of glycoprotein Ⅱb/Ⅲa in hibitors in invasively-treated patients with non-ST elevation acute coronary syndrome [J]. J Cardiovasc Med (Hagerstown),2006,7(3):159-165.
[87]Fitchett DH, Langer A.Armstrong PW, et al. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein Ilb/IIIa inhibitor eptif ibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment(INTERACT) trial[J]. Am Heart J,2006,151(2):373-379.
[88]Curran MP, Keating GM. Eptif ibatide:a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention[J]. Drugs,2005,65(14): 2009-2035.
[89]Puma JA, Banko LT, Pieper KS, et al. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting:insights from the Enhanced Suppression of the Platelet Ilb/IIIa Receptor With Integrilin Therapy(ESPRIT)trial[J]. J Am Coll Cardiol,2006,47(4):715-718.
[90]Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate-to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide:observations from the PROTECT-TIMI-30 trial [J]. J Am Coll Cardiol,2006,47(12): 2374-2379.
[91]0'Naill WW, Serruys P, Knudtson M, et al. Long-term treatment with Aplatelet glycoprotein2recep torantagonist after percutaneous coronary revascularization [J]. N Engl J Med,2000,342 (17):1316-1324.
[92]The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes[J]. Circulation,2001,103(13): 1727-1733.
[93]Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Circulation,2009,119(25):3207-3214.
[94]King SB, Smith SC, Hirshf eld JW, et al.2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention [J]. Circulation,2008,117(2):261-295.
[95]Pothiwala RA, TanwarNS, Ranjan A, et al. Efficacy and safety of high loading dose clopidogrel regimen prior to coronary stent implantation [J]. Indian Heart J,2004,56:A496.
[96]Brandt JT, Payne CD, Weerakkody G, et al. Superior responder rate for inhibition of platelet aggregation with a 60mg loading dose of prasugrel (CS2747, LY640315) compared with a 300 mg loading dose of clopidogrel[J]. J Am Coll Cardiol,2005,45:87A.
[97]Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS2747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity [J]. Semin Thromb Hemost,2005,31:184-194.
[98]Peters G, Robbie G. Single dose pharmacokinetics and pharmacodynamics of AZD6140:an oral reversible ADP receptor antagonist[J]. Hematologica,2004,89:14-15.
[99]Husted S, Emanuelsson H, Heptinstall S,et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a double-blind comparison to clopidogrel with aspirin[J]. Eur Heart J, 2006,27:1038-1047.
[1]贺铁豪,高国政,张奇峰.脑心通胶囊治疗冠心病心绞痛40例[J].辽宁中医杂志,2010,37(5)：866-867.
[2]刘静秋.步长脑心通治疗冠心病心绞痛疗效观察[J].中国社区医师,2010,12(227)：73.
[3]马晓梅,赵占丽.脑心通胶囊治疗冠心病心绞痛32例临床观察[J].首都医药,2010,(12)：55-56.
[4]陈明清,王柽鑫,李玉华,等.步长脑心通胶囊长期治疗冠心病的临床疗效观察[J].医学实践与理论,2010,23(4)：402-403.
[5]邱清华,彭玉玺,齐昕,等.步长脑心通和辛伐他汀预防冠心病合并糖尿病冠状动脉支架内再狭窄的疗效观察[J].当代医学,2010,16(5):29-30.
[6]姚品芳.丹红注射液联合脑心通治疗无症状性心肌缺血的临床疗效观察[J].当代医学,2009,15(34)：139-140.
[7]卫海松,高海旺,王亮亮,等.步长脑心通胶囊治疗冠状动脉慢血流的临床研究[J].慢性病学杂志,2010,12(9)：1019-1020.
[8]贺志伟,李力明,邹迪贵,等.脑心通对急性心肌梗死患者再灌注后心肌和微血管的影响观察[J].中国实用医药,2010,5(17)：166-168.
[9]张志诚,刘建华,林振起,等.脑心通胶囊对急性冠脉综合征患者颈动脉斑块和血清超敏c反应蛋白的影响[J].中医杂志,2010,51(4)：329-331.
[10]张兆源.脑心通对急性冠脉综合征相关因子影响的研究[J].人民军医,2010,53(12)：926-927.
[11]关良劲,钟汉林,王珊,等.步长脑心通对急性冠状动脉综合征血清基质金属蛋白酶及其抑制物水平的影响[J].岭南急诊医学杂志,2007,12(6)：414-415.
[12]杨国栋,高天宇.步长脑心通改善冠心病左心功能的临床研究[J].内蒙古中医药,2008,3：5-6.
[13]陈勇,缪灿铭,陈正贵,等.脑心通治疗老年心力衰竭的疗效观察[J].中西医结合心脑血管病杂志,2005,3(7)：603-604.
[14]胡美琴,崔伟娜,徐玉兰.脑心通对肥胖原发性高血压瘦素水平影响的研究[J].人民军医,2010,54(1)：36-37.
[15]王莹,吴相得,贾连旺.脑心通胶囊对老年单纯收缩期高血压血管内皮舒张功能影响的超声评价[J].中华中医药学刊,2008,28(3)：657-659.
[16]颜文涛.步长脑心通治疗老年人原发性高血压的临床疗效观察[J].实用心脑肺血管病杂志,2008,16(11)：34.
[17]孟秀清.脑心通治疗脑梗死疗效观察[J].亚太传统医药,2010,6(9)：32-33.
[18]张天华,王松龄.步长脑心通胶囊治疗急性脑梗死的临床观察[J].光明中医,2010,25(10) ：1844-1845.
[19]刘建书,贺永红.脑心通治疗脑梗死的临床观察[J].中国民康医学,2010,22(10)：1258.
[20]何建明,李玉蓉,韦英秀,等.脑心通胶囊对急性脑梗死患者血清血管内皮细胞生长因子水平影响的研究[J].医学研究杂志,2010,39(11)：36-38.
[21]粟显才,伍玉锋.步长脑心通胶囊对短暂性脑缺血发作患者血清超敏C反应蛋白的影响[J].实用心脑肺血管病杂志,2010,18(10)：1447-1448.
[22]张月明,鲁东。王冶.步长脑心通联合阿司匹林治疗短暂性脑缺血发作疗效观察[J].中国当代医药,2010,17(13)：104-105.
[23]钟玲.脑心通胶囊配合醒脑开窍针刺法治疗脑血管病偏瘫临床研究[J].辽宁中医杂志,2010,37(7)：1288-1289.
[24]杨志军.脑心通胶囊结合康复疗法对缺血性脑卒中恢复期的疗效验证[J].吉林医学,2010,31(5)：617-618.
[25]高立,张宗艳,王莉,等.脑干听觉诱发电位和经颅多普勒超声对脑心通治疗椎基底动脉短暂缺血性眩晕的疗效观察[J].临床荟萃,2010,25(20)：1809-1811.
[26]张秀忠,张德新,徐海樱.步长脑心通在缺血性脑血管病二级预防中的疗效观察[J].实用心脑肺血管病杂志,2008,16(12)：37.
[27]葛近峰,何爱芳,宁子秀.步长脑心通胶囊合高压氧治疗血管性痴呆36例[J].辽宁中医杂志,2010,37(6)：1050-1051.
[28]冯辉,张雪梅,刘彩莉.步长脑心通联合丁咯地尔治疗血管性痴呆临床观察[J].辽宁中医药大学学报,2008,10(10)：88-90.
[29]蔡敏,马绿曦,罗春阳,等.步长脑心通治疗血管性痴呆的临床分析[J].重庆医学,2008,37(21)：2453-2454.
[30]郭宝珠.步长脑心通治疗118例冠心病合并高血脂患者疗效分析[J].青海医药杂志,2010,40(8)：12-13.
[31]韩知.步长脑心通配合足浴治疗糖尿病周围神经病变疗效观察[J].亚太传统医药,2010,6(9)：37-38.
[32]仲崇涛,闫洪泉.丹红注射液加脑心通胶囊治疗Ⅰ期糖尿病足疗效观察[J].人民军医,2010,53(9)：687-688.
[33]姜凤琴,宗高庚,许道营,等.脑心通对2型糖尿病微血管病变患者血小板活化功能的影响[J].山东医药,2007,47(13)：58.
[34]戴铁军.脑心通配合西药治疗2型糖尿病视网膜病变24例临床观察[J].云南中医中药杂志,2007,28 (7)： 12.
[35]张书申,王芳,乔苏民.脑心通胶囊联合福辛普利治疗早期糖尿病肾病[J].中国中西医结合心脑血管病杂志,2007,5(12)：1180-1181.
[36]郭立东,穆克代斯,桑晓红.步长脑心通胶囊对慢性肾炎患者的血流变及血脂的影响[J].中国实用医药,2008,3(11):44-45.
[37]罗玉军.步长脑心通治疗痔疮的疗效观察[J].实用医技杂志,2007,14(13)：1807.
[38]万敏娜,金钟奎,万洁华,等.脑心通胶囊在治疗慢性肺源性心脏病的临床研究[J].中国实用 医药,2010,5(20)：163-164.
[39]王振峰,张华,崔之娟,等.步长脑心通胶囊治疗紧张性头痛的远期疗效观察[J].中国医药导报,2010,7(10)：109-110.
[2]Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet,2001,358(9281):527-533.
[3]Steinhubl SR, Berger PB, Mann JT Ⅲ, et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[4]Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction:randomised placebo-controlled trial[J]. Lancet,2005, 366 (9497):1607-1621.
[5]Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme:rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease[J]. Eur Heart J,2000,21 (24): 2033-2041.
[6]Fox KA, MehtaSR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome:the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial[J]. Circulation,2004,110 (10):1202-1208.
[7]Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy formyocardial infarction with ST-segment elevation[J].N Engl J Med, 2005,352 (12):1179-1189.
[8]Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction[J]. Circulation,2003,108:11128-11137.
[9]Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weigh heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention[J]. JAMA,2003, 289:331-342.
[10]任毅,吴瑜,张敏州,等.冠心病介入治疗围术期中医证候特征及分布规律的研究[J].中西医结合心脑血管病杂志,2010,8(6)：639-641.
[11]李健,张敏州,林晓忠,等.冠状动脉介入术对冠心病气虚血瘀证影响的临床研究[J].中西医结合心脑血管病杂志,2007,5(11)：1040-1041.
[12]陈伯钧,潘宗奇,苏学旭,等.冠心病介入治疗前后中医证型变化的研究[J].中国中西医结合杂志,2007,27(8)：689-691.
[13]李健,张敏州,陈伯钧,等.通冠胶囊对冠心病介入术后气虚血瘀证患者的影响[J].中国中西医 结合杂志,2008,28(1)：32-35.
[14]管琳,张宁宁,尹承娥.近10年来气虚血瘀型冠心病的研究概况[J].山东中医杂志,2002,21(5)：316-317.
[15]覃乔静,李荣亨.气虚血瘀证血浆NPY, ET\CGRP的改变及相关性研究[J].重庆医科大学学报,2003,28(2)：202-204.
[16]曾志立,李荣亨.气虚血瘀证患者血浆AM\ET\CGRP, NPY的变化及意义[J].中国中医基础医学杂志,2004,10(3)：22-23.
[17]荣晓凤,李荣亨,吕霞.气虚血瘀证大鼠NO. EX. TXB2.6-Keto-PGFu的变化及意义[J].中国中医基础医学杂志,2009,15(12)：914-916.
[18]赵慧辉,侯娜,王伟.冠心病气虚血瘀证的蛋白质组学特征研究[J].中国中西医结合杂志,2009,29(6)：489-492.
[19]何庆勇,王阶,张允岭,等.冠心病介入术后再狭窄危险因素及中医证候要素分析[J].北京中医药大学学报,2008,31(8)：569-572.
[20]Hulot JS, Bura A, Villard E, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood,2006, 108(7):2244-2247.
[21]Miao J, Liu R, Li Z, et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(21):2250-2251.
[22]Trenk D, Hochholzer W, FrommM F, et al. Cytochrome P4502C19681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol,2008,51(20):1925-1934.
[23]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
[24]GiustiB, Gori AM, Marcucci R, et al. Cytochrome P4502C19 loss of function polymorphism, but not CYP3A4IVS10+12GPA and P2Y12 T744C polymorphisms, is associated with response variability to dual、antiplatelet treatment in high risk vascular patients[J]. Pharmacogenet Genomics,2007,17(12)：1057-1064.
[25]Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study[J]. Lancet,2009; 373(9660):276-278.
[26]Huang MW, Wang H, Zhong WJ, et al. Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi[J]. J Chin Integr Med,2011; 9(1):38-47.
[27]Chen H, Yu GW, Sun H, et al. Comparison of adjunctive naoxintong versus clopidogrel in volunteers with the CYP2C19*2 gene mutation accompanied with qi deficiency and blood stasis constitution[J]. Evid Based Complement Alternat Med,2011:207034:1-10.
[28]陈灏珠.实用内科学[M].第12版.北京：人民卫生出版社,2005,1472-1473.
[29]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002:68-73.
[30]Mathers C, Bemard C, Iburg K, et al. Global Burden of Disease in 2002:Data Sources, Methods and Results[R]. GPE Discussion PaPer No.54. Geneva:World Health Organization,2004.
[31]Alm-Roi jer C, Stagmo M, Uden G, et al. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease [J]. Eur J Cardiovasc Nurs, 2004,3(4):321-330.
[32]杨祖福.心脏康复及其在我国的发展[J].中国康复理论与实践,2008,14(4):301-302.
[33]Singh M, Rihal CS, Gersh BJ, et al. Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary intervention:a single-institution expertience[J]. circulation,2007,115 (22):2835-2841.
[34]王师菡,王阶,何庆勇,等.冠心病介入术后中医证候要素分布规律及相关因素分析[J].世界科学技术—中医药现代化,2008,10(6)：11-15.
[35]Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis[J]. Haemophilia,2008,14:11-26.
[36]Ribes JA.Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells[J]. J Clin Invest,1987,79 (1):117-123.
[37]Cruz MA.Whitelock J, Don JF. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand factor A2 domain polypeptide as substrate[J]. Thromb Haemost, 2003,90(6):1204-1209.
[38]DenisCV, Christoph OD, Oortwi jn BD, et al. Clearance of von Willebrand factor [J]. Thromb Haemost,2008,99(2):271-278.
[39]Reininger AJ. vWF attributes-impact on thrombus formation[J]. Thromb Res,2008,122: S9-S13.
[40]MiuraS, Li CQ, CaoZ, et al. Interaction of von Willebrand factor domain Al with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion[J]. J Biol Chem,2000,275:7539-7546.
[41]Bonnefoy A, Yamamoto H, Thys C, et al. Shielding the front-strand beta 3 of the von Willebrand factor Al domain inhibits its binding to platelet glycoprotein Ibalpha[J]. Blood,2003,101:1375-1383.
[42]LipGY, Lydakis C, NuttallSL, et al. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction[J]. J Intern Med, 2000,248:316-318.
[43]Fuchs I, Frossard M, Spiel A, et al. Platelet function in patients with acute coronary syndrome(ACS) predicts recurrent ACS[J]. J Thromb Haemost,2006,4:2547-2552.
[44]Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention:insights into the STRATEGY Study[J]. J Am Coll Cardiol,2006,48:2178-2185.
[45]Blann A, Midgley H, Burrows G, et al. Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty[J]. Coron Artery Dis,1993, 4:905-910.
[46]Heper G, Murat SN, Durmaz T, et al. Prospective evaluation of von Willebrand factor release after multiple and single stenting[j]. Angiolog,2004,55:177-186.
[47]Boos CJ, Balakrishnan B, Jessani S, et al. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction[J]. Chest,2007,132(6):1920-1926.
[48]Coutts RT, Unchuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry[J]. Cell Mol Neurobiol,1999,19(3):325-354.
[49]韩运峰,冯艳萍,张树林.氯吡格雷抵抗的药物基因组学研究进展[J].中国分子心脏病学杂志,2010,(4)：249-253.
[50]Wedlund PJ.The CYP2C19 enzyme polymorphism[J]. Pharmacology,2000,61(3):174-183.
[51]Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[52]Liu XL, Wang ZJ, Yang QL, et al. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease[J]. Chin Med J,2010, 123(22):3178-3183.
[53]KangMK, Jeong YH, Yoon SE, et al. Pre-procedural platelet reactivity after clopidogrel locding in korean patients undergoing scheduled percutaneous coronary intervention[J]. J Atheroscler Thromb,2010,17(11):1122-1131.
[54]Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P4502C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel[J]. Circ J,2010,75(1):99-105.
[55]Chen H, Yan W, Wu XY. Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis [J]. Zhong guo Zhong Xi Yi Jie He Za Zhi, 2010,30(12):1245-1249.
[56]Matek LA, Przytuski J, Spiewak M, et al. Cytochrome P4502C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction[J]. Cardiology,2010,117(2):81-87.
[57]Harmsze AM, van Werkum JW, Ten Berg JM, et al.CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis:a case-control study[J]. Eur Heart J,2010,31(24): 3046-3053.
[58]Sadowitz B, Maier KG, Gahtan V. Basic science review:Statin therapy--Part I:The pleiotropic effects of statins in cardiovascular disease [J]. Vase Endovascular Surg,2010, 44(4):241-251.
[59]Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation,2003,107 (1):32-37.
[60Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet functiona flow cytometry study [J]. Eur Heart J,2003,24 (19):1744-1749.
[61]Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy[J]. Eur J Clin Invest,2005,35 (8):476-481.
[62]Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J]. Circulation,2003,108 (18):2195-2197.
[63]Gorehakova 0, von Beckerath N, Gawas M, et al. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting[J]. Eur Heart J,2004,25 (21): 1898-1902.
[64]Saw J, Steinhubl SR, BergerPB, et al. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial[J]. Circulation,2003,108 (8):921-924.
[65]Serrano Junior CV, Soeiro Ade M, Araiijo LF, et al. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation[J]. Arq Bras Cardiol,2010,95(3): 321-327.
[66]Han YL, Zhang ZL, Li Y, et al. Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting:a randomized controlled trial[J]. Zhong hua Yi Xue Za Zhi,2009,89(32):2240-2244.
[67]Blagojevic A, Delaney JA, Levesque LE, et al. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention:a cohort study[J]. Pharmacoepidemiol Drug Saf,2009,18(5):362-369.
[68]Geisler T, ZUrn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Eur Heart J,2008,29(13):1635-1643.
[67]Zhang ZJ, Marroquin 0C, Weissfeld JL, et al. Beneficial effects of statins after percutaneous coronary intervention [J]. Eur JCardiovasc Prev Rehabil,2009,16(4):445-450.
[70]Kim MC, Ahn Y, Cho KH, et al. Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction[J]. Int Heart J,2011,52(1):1-6.
[71]Shibui T, Nakagomi A, Kusama Y, et al. Impact of statin therapy on renal function and long-term prognosis in acute coronary syndrome patients with chronic kidney disease[J]. Int Heart J,2010,51(5):312-318.
[72]ISHZAKI T, HORAI Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole[J]. Alinment Pharmacol Ther,1999。13:27-36.
[73]EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS WE. Pharmacogenomics and individualized drug therapy[J]. Annu Rev Med,2006,57:119-137.
[74]GARDINER J, BEGG J. Pharmacogenetics, drug-metabolizing enzymes, and clinical pratice[J]. Pharmacol Rev,2006,58(3):521-590.
[75]Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009,180 (7):713-718.
[76]Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following cute coronary syndrome[J].JAMA, 2009,301 (9):937-944.
[77]Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101 (4):714-719.
[78]Gaspar A, Ribeiro S, Nabais S, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome [J]. Rev Port Cardiol,2010,29(10): 1511-1520.
[79]Yasu T, Ikee R, Miyasaka Y, et al. Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation:a retrospective cohort study[J]. Yakugaku Zasshi,2010,130(12):1743-1750.
[80]SimonT, Steg PG, Gilard M, et al. Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction:Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry[J]. Circulation,2011,123(5): 474-482.
[81]0rtolani P, Marino M, Marzocchi A, et al. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study[J]. J Cardiovasc Med (Hagerstown),2011 Jan 19. [Epub ahead of print].
[82]Banerjee S, Weideman RA, Weideman MW, et al. Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention[J]. Am J Cardiol,2011 Jan 17. [Epub ahead of print].
[83]Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors:a systematic review[J]. BMC Med,2010,8:81.
[84]Moran N, Kiernan A, Dunne E, et al. Monitoring modulators of platelet aggregation in a microtiter plate assay[J]. Anal Biochem 2006; 357 (7):77-84.
[85]Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting:results of the PREPARE POST-STENTING Study[J]. J Am Coll Cardiol, 2005,46(10):1820-1826.
[86]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation,2004,109(25):3171-3175.
[87]Samara WM, Bliden KP, Tantry US, et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity[J]. Thromb Res,2005,115(1-2):89-94.
[88]Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS lb study[J]. J Am Coll Cardiol,2006,48(11):2186-2191.
[89]Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention:a potential antiplatelet therapeutic target[J]. Platelets,2008,19(8):595-604.
[90]Spiel AO, Gilbert JC, Jilma B. Von Willebrand Factor in Cardiovascular Disease:Focus on Acute Coronary Syndromes[J]. Circulation,2008; 117:1449-1459.
[91]Paulinska P, Spiel A, Jilma B. Role of von Willebrand factor in vascular disease[J]. Hamostaseologie,2009,29(1):32-38.
[92]吕芳芳,黄文.冠心病心绞痛不同证型与血液流变关系的探讨[J].北京中医,2004,23(6)：327-328.
[93]史培圣.冠心病气滞血瘀与气虚血瘀证型微循环比较[J].实用中西医杂志,1991,(3)：145-147.
[94]赖真,郭恕.冠心病心绞痛气虚血瘀与气滞血瘀的微循环变化[J].湖南中医学院学报,1994,(3)：441.
[95]赖世隆.血瘀证、气虚血瘀证患者TXA2、PGI2水平与微循环观察及其相关性分析[J].中国医药学报,1990,(6)：14-17.
[96]赖真,汪建红.冠心病心绞痛气虚血瘀和气滞血瘀的微循环变化[J].湖南中医学院学报,1994,14 (3)：44.
[97]刘家骏.气滞血瘀与气虚血瘀患者病理生理学的初步探讨[J].中医杂志,1991,(9)：46-47.
[98]林港祥.常见心血管病气滞血瘀、气虚血瘀证血液流变学变化[J].贵州医学,1993,(3)：185-187.
[99]孙锡印,段学忠.冠心病中医证型间血液流变性的异同及辨治对其影响[J].中医药研究,1997,(1)：121.
[100]袁肇凯,杨运高.气滞血瘀与气虚血瘀辨证微观指标的观察分析[J].中医杂志,1995,(8)：565-567.
[101]赵慧辉,陈建新,史琦,等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究[J].中国中西医结合杂志,2010,30(5)：488-492.
[102]张继东,乔云,武传龙,等.冠心病患者胰岛素抵抗与中医辨证分型及纤溶系统活性的相关性研究[J].中国中西医结合杂志,2004,24(5)：408-410.
[103]张宁宁,尹承娥,吕芳芳,等.气滞血瘀、气虚血瘀心绞痛患者心率变异性与心肌缺血指数相关性探讨[J].山东中医药大学学报,2003,27(2)：123-124.
[104]谷旭放.冠心病心绞痛气虚血瘀证与气滞血瘀证平板运动试验结果对照分析[J].中国全科医学,2010,13(6A)：1808-1812.
[105]杨东辉,孙博,郭艳艳.冠心病患者中医证型与颈动脉内膜-中层厚度及踝臂指数的相关性研究[J].云南中医中药杂志,2009,30(9)：5-6.
[106]朱萱萱,王广基,达庆国,等.冠心病中医证型与冠状动脉造影的相关性研究[J].中华中医药学刊,2010,28(8)：1579-1581.
[107]贾玉柱,沈盛晖,祁克信,等.冠心病中医证候与16层螺旋CT冠状动脉造影的相关性分析[J].中国中医急症,2010,19(10)：1703-1704.
[108]朱翠玲,闫奎坡,朱明军,等.冠心病中医证型与冠状动脉病变的相关性研究[J].中国中药杂志,2009,34(24)：3289-3291.
[109]胡元会,吴林,周次清.经皮冠状动脉介入治疗后再狭窄的中医病机治法钩玄[J].中国中医基础医学杂志,2003,9(2)：14-16.
[110]潘毅.心气虚证计量诊断再探[J].广州中医学院学报,1995,12(1)：10—13.
[111]陈可冀.活血化瘀研究与临床[M].北京：北京医科大学中国协和医科大学联合出版社,1993：3-7.
[112]Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase[J]. J Am Coll Cardiol,1988,11 (1):1-11.
[113]0ng AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal sirolrmus or paclitaxel stent implantation[J]. J Am Coll Cardiol,2005,45(6):947-953.
[114]Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents[J]. JAMA,2005,293(17):2126-2130.
[115]Kereiakes DJ, Choo JK, Young JJ, et al. Thrombosis and drug-eluting stents:a critical appraisal[J]. Rev Cardiovasc Med,2004;5(1):9-15.
[116]Fenwei W, Stouffer GA, Waxman S, et al. Late coronary stent thrombosis:Early vs late stent thrombosis in the stent era. Commentary[J]. Catheterization and Cardiovascular Interventions,2002,55(2):142-149.
[117]Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents[J]. N Engl J Med,2007,356(10):1020-1029.
[118]陈立娟,马根山,冯毅,等.紫杉醇药物涂层支架治疗左前降支病变临床研究[J].东南大学学报：医学版,2006,25(6)：423-426.
[119]Tsimikas S. Drug-eluting stents and late adverse clinical outeomes lessons learned, lessons awaited[J].J Am Coll Cardiol,2006,47(10):2112-2125.
[120]Rodriguez AE, Mieres J, Fernandez-Pereira C, et al.Coronaty stent. Thrombosis in the current drug-eluting stent era:insights from the ERACI HI trial[J].J Am Coll Cardiol, 2006,47(1):205-207.
[121]Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease[J].J Am Coll Cardiol,2007,50(19):1822-1834.
[122]The EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa in high risk coronary angioplasty[J].N Engl J Med,1994,330:956-961.
[123]EPILOG Investigators. Platelet glycoprotein Ⅱb/Ⅲa blockade with abciximab with low dose heparin during percutaneous coronary revascularization[J].N Engl J Med,1997,336: 1689-1696.
[124]EPISTENT Investigators. Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein Ⅱb/Ⅲa blockade[J]. Lancet,1998,352:87-92.
[125]CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina:the CAPTURE study[J]. Lancet, 1997,349:1429-1435.
[126]IMPACT Ⅱ Investigators. Randomized placebo controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT Ⅱ [J]. Lancet, 1997,349:1422-1428.
[127]The RESTORE Investigators. Effect of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction[J]. Circulation,1997,96:1445-1453.
[128]Christersson C, Oldgen J, Bylock A, et al. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events:Observations from the ESTEEM trial[J]. Eur Heart J,2007; 28 (6):692-698.
[129]Vischetti M, Zito F, Donati MB, et al. Analysis of gene enviorment irrteraction in coronary heart disease:fibrinogen polymorphisms as an example [J]. Ital Heart J,2002; 3 (1):182-231.
[130]Coppola G, Rizzo M, Abrignami MG, et al. Fibrinogen as a predictor of mortality after acute myocardial infarction:a forty-two month follow-up study[J]. Ital Heart J,2005; 6 (4):315-322.
[131]赵步长,伍海勤,赵涛主编.脑心同治—心脑血管疾病防治进展[M].北京：人民卫生出版社,2006：298-334.
[132]张艳玲,莫炜,王龙生,等.重组双功能水蛭素抗凝防栓作用的实验研究[J].中华手外科杂志,2006,22(2)：106-108.
[133]顾立新.脑心通胶囊治疗冠心病心绞痛气虚血瘀证的疗效观察[J].中西医结合心脑血管病杂志,2006；4(10)：925-926.
[134]王凤科.步长脑心通胶囊对冠心病患者血粘度与内皮细胞功能的影响[J].山东医药,2007;47(28)：70-71.
[135]陈达开,张怀勤,张建华.脑心通胶囊对阿司匹林抗血小板治疗的影响[J].中医杂志,2008;49(7)：605-607.
[136]张加力,杜立树,平龙玉,等.脑心通胶囊对87例冠心病患者血清CPR的影响[J].中医杂志,2006;47(6)：472-473.
[137]任丁,吴云虎,黄建民,等.脑心通胶囊对血管支架成型术后再狭窄预防作用的研究[J].中西医结合心脑血管病杂志,2009；7(3)：361-362.
[138]吴发宝,陈希元.黄芪药理研究综述[J].中药材,2004,23(7)：233-234.
[139]夏泉,张平,李邵平,等.当归的药理作用研究进展.时珍国医国药[J],2004,15(3)：16-18.
[140]胡芬,向继洲.中药治疗血小板性紫癜的药理作用.医药导报[J],2005,24(6)：480-482.
[141]陈东辉,罗霞,余梦瑶,等.鸡血藤煎剂对小鼠骨髓细胞增殖的影响[J].中国中药杂志,2004,29(4)：352—355.
[142]Vol Bohr C, Groth CG, Jansson H, et al. Drug metabolism in human liver in vitro:Establishment of a human liver bank[J].Clin Pharmacol Ther,1980,27:711-723.
[143]Bray ton CF, Dimethyl sulfoxide (DMSO):areview[J]. Cornell Vet,1986,76 (1):61-90.
[144]Glockner R, Steinmetzer P, Drobner C. Application of cryopreserved precision-cut liver slices in pharmacotoxicology-principles, literature data and own investigations with special reference to CYPlAl-mRNA induction[J]. Exp Toxicol Pathol,1998,50(4-6):440-449.
[145]Hengstler JG, Utesch D, Steinberg P, et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction[J]. Durg Metab Rev,2000,32(1):81-118.
[146]李焕德,李坤艳.药物代谢性相互作用体外研究的重要性[J].中南药学,2005,3(3)：179-181.
[147]王汝龙.三哇类抗深部真菌药的临床药学进展[J].临床药物治疗杂志,2007,5(1):1-7.
[1]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002:68-73.
[2]全国冠心病辨证论治研究座谈会.冠心病中医辨证试行标准[J].中医杂志,1980,(8)：46.
[3]中西医结合心血管学会.冠心病的中医辨证标准[J].中西医结合杂志,1991,11(5)：257.
[4]孙春霞,颜乾麟,黄书慧,等.1001例冠心病介入术后患者中医证候调查[J].中医杂志,2010,51(9)：827-829.
[5]任毅,吴瑜,张敏州,等.冠心病介入治疗围术期中医证候特征及分布规律的研究[J].中西医结合心脑血管病杂志,2010,8(6)：639-641.
[6]李健,张敏州,林晓忠,等.冠状动脉介入术对冠心病气虚血瘀证影响的临床研究[J].中西医结合心脑血管病杂志,2007,5(11)：1040-1041.
[7]陈伯钧,潘宗奇,苏学旭,等.冠心病介入治疗前后中医证型变化的研究[J].中国中西医结合杂志,2007,27(8)：689-691.
[8]王师菡,王阶,何庆勇,等.冠心病介入术后中医证候要素分布规律及相关因素分析[J].世界科学技术—中医药现代化,2008,10(6)：11-15.
[9]何庆勇,王阶.基于聚类分析的冠心病介入术后中医证候分类及诊断[J].中医杂志,2008,49(10)：918-921.
[10]李世林,程伟,王鹏.冠心病药物洗脱支架植入患者介入前后中医证型变化的研究[J].中西医结合心脑血管病杂志,2010,8(2)：151-152.
[11]严卉,胡晓晟,陈君柱,等.血浆同型半胱氨酸和冠状动脉粥样硬化严重程度与中医证型的关系[J].中国中西医结合杂志,2002,22(11)：813-815.
[12]方显明,唐耀平,郑德俊.冠心病血浆同型半胱氨酸与中医证型的相关性[J].中医杂志,2005,46(10)：775-776.
[13]蒋华,赵永东.冠心病患者血浆同型半胱氨酸水平与中医辨证分型的相关性研究[J].新疆中医药,2008,26(4)：23-25.
[14]刘敏,张培影.不稳定性心绞痛中医证型与Hcy、hs-CRP的关系[J].浙江中西医结合杂志,2009,19(7)：406-407.
[15]尤卫平,石磊,韦爱欢,等.冠心病中医辨证分型与内皮损伤、炎症反应及血小板活化的相关性研究[J].广州中医药大学学报,2008,25(5)：457-460.
[16]陈玉婷,胡娟娟,余姚,等.冠心病痰瘀辨证分型与相关生化指标关系探讨[J].浙江中西医结合杂志,2005,15(3)：144-146.
[17]林超,郭进建,林青,等.高敏C反应蛋白与不稳定型心绞痛中医证型相关性研究[J].中国中医急症,2007,16(10)：1221-1223.
[18]商秀洋,石洁.冠心病中医辨证与血清高敏c反应蛋白的关系研究[J].现代中西医结合杂志,2008,17(6)：818-820.
[19]郑峰,曲丹,徐浩,等.冠心病稳定期患者中医辨证与超敏c反应蛋白相关性研究[J].中国中西医结合杂志,2009,29(6)：485-488.
[20]李创鹏,刘培中,刘克锋,等.冠心病辨证分型与心血管危险因素相关性研究[J].新中医,2010,42(9)：35-37.
[21]朱翠玲,何卫士,朱明军,等.FIB与冠心病中医证型及体质量的相关性研究[J].中医学报,2010,25(151)：1151-1153.
[22]龙卫平,陈剑,何汉康,等.女性冠心病患者中医证型及冠状动脉造影特点的研究[J].上海中医药大学学报,2010,24(4)：45-47.
[23]王子宽,柳荫,李波,等.冠心病危险因素与中医证型相关性分析[J].陕西中医学院学报,2008,31(6)：6-8.
[24]于顾然,贺燕勤,郭云庚,等.冠心病中医证型与胰岛素抵抗、脂质及红细胞膜ATP酶关系的临床研究[J].中医杂志,2000,41(2)：111-112.
[25]王洪泉.冠心病血脂异常与中医辨证关系研究[J].中国社区医生,2010,12(248)：135.
[26]魏丹霞,刘明,庞永诚,等.冠心病患者血脂水平与中医辨证分型的相关研究[J].中国中医急症,2010,19(3)：441-442.
[27]褚福永,王阶,姚魁武,等.冠心病不稳定型心绞痛中医辨证分型与血脂及冠脉造影结果的相关性研究[J].北京中医药,2009,28(12)：918-921.
[28]刘明,魏丹霞,陈奇刚,等.急性心肌梗死患者血脂水平变化与中医辨证分型的临床研究[J].中国中西医结合急救杂志,2001,8(1)：29-30.
[29]其其格,王伟,毕力夫,等.冠心病血瘀证与血脂血尿酸关系的探讨[J].辽宁中医杂志,2008,35(12)：1826-1827.
[30]唐巍,遇红,李江涛,等.冠心病患者血中胰岛素、胰高血糖素与中医证候类型关系的研究[J].中国中医基础医学杂志,2002,8(9)：53-55.
[31]陈晓虎,徐顺娟.冠心病(胸痹)胰岛素抵抗与中医辨证分型关系的临床研究[J].南京中医药大学学报,2006,22(5)：296-298.
[32]张继东,乔云,武传龙,等.冠心病患者胰岛素抵抗与中医辨证分型及纤溶系统活性的相关性研究[J].中国中西医结合杂志,2004,24(5)：408-410.
[33]王阶,李霁,杨戈.外周血白细胞与冠状动脉狭窄程度及冠心病中医证型之间的关系[J].中国中西医结合杂志,2010,30(2)：130-132.
[34]尹克春,罗翌,曾星.冠心病血瘀证病人血白细胞CD11b/CD18表达的研究[J].中西医结合心脑血管病杂志,2003,1(7)：381-383.
[35]贺劲.血液流变性改变与冠心病中医证型关系研究[J].中国中医急症,2008,17(10)：1401-1403.
[36]曹雪明,张泉,郑重,等.冠心病中医证型与血液流变学相关性探讨[J].中国中医急症,2006,15(11)：1242-1243.
[37]李越华,肖沪生.冠心病中医辨证分型与心功能及血液流变学之间关系的研究[J].辽宁中医杂志,2004,31(12)：998-999.
[38]丘瑞香,罗致强,宋雅宜,等.冠心病血瘀证血液理化特性与中医证型相关性研究[J].中医杂志,2002,43(5)：378-390.
[39]张冬梅,陈建鸿,祝梅华.冠心病中医辨证与血液流变学的关系[J].现代福州总医院学报,1999,6(2)：42-43.
[40]吕芳芳,黄文.冠心病心绞痛不同证型与血液流变关系的探讨[J].北京中医,2004,23(6)：327-328.
[41]赖真,汪建红.冠心病心绞痛气虚血瘀和气滞血瘀的微循环变化[J].湖南中医学院学报,1994,14 (3)：44.
[42]李进兵,冯靖禧,陈伯钧,等.冠心病稳定型心绞痛中医证型与血管内皮功能相关性研究[J].世界中西医结合杂志,2010,5(8)：688-691.
[43]陈昕琳,顼志兵,顾仁樾.vWF、Ps.水平与冠心病中医证型相关性的临床研究[J].湖北中医杂志,2007,29(8)：11-12.
[44]梁知,顼志兵,顾仁樾.冠心病中医证型与P-选择素相关性的临床研究[J].辽宁中医杂志,2006,33(12)：1595-1596.
[45]梁知,项志兵,顾仁樾.血管性血友病因子、血栓素B2及6-酮-前列环素与冠心病中医证型相关性的临床研究[J].上海中医药杂志,2006,40(6)：13-14.
[46]徐采云,邢之华,刘卫平,等.冠心病不同中医证型与血浆纤维蛋白原的相关性研究[J].中医康复,2010,25(3)：190-192.
[47]王娟,安冬青.冠心病秽浊痰阻证与纤维蛋白原和血栓前体蛋白的关系探讨[J].云南中医中药杂志,2010,31(4)：18-19.
[48]孙红艳,安冬青,宋刚,等.冠心病秽浊痰阻证与血浆t-PA、PAI-1及Fib的相关性研究[J].中西医结合心脑血管病杂志,2009,7(4)：389-391.
[49]吕中,施赛珠,祝光礼.冠心病患者单核细胞凝血／纤溶活性改变与中医证型关系[J].中国中医基础医学杂志,2001,7(3)：59-61.
[50]莫鸿辉,黄衍寿,洪永敦,等.黏附分子-1血清水平及基因多态性与冠心病痰瘀证候关系研究[J].新中医,2009,41(11)：25-28.
[51]王强,程胜军.冠心病心绞痛中医证型与IL-18、hs-CRP的相关性探讨[J].广西中医药,2008,31(4)：14-15.
[52]雷瑗琳,乔会侠,赵明君.冠心病合并肥胖症患者血清瘦素水平与中医证候的相关性研究[J].陕西中医,2008,29(6)：645-646.
[53]李成林,王庆高,朱智德.冠心病心绞痛中医证型与脑钠肽、C-反应蛋白和肌钙蛋白相关性研究[J].新中医,2008,40(7)：32-33.
[54]林桂永,阮威君.急性冠脉综合征痰瘀证与炎症关系的临床研究[J].中国民康医学,2008,20(9)：872-875.
[55]李俊,王大伟,严夏,等.冠心病不稳定型心绞痛中医证候与C-反应蛋白和基质金属蛋白酶-9关系的研究[J].辽宁中医药大学学报,2008,10(2)：102-103.
[56]杨徐杭,汶医宁,党琳,等.冠心病中医辨证与血清E-选择素、细胞间粘附分子-1的关系研究[J].四川中医,2008,26(1)：61-62.
[57]李静,张继东,刘同涛.血清胆红素与冠脉病变程度、血脂及冠心病中医证型关系[J].南京中医药大学学报,2006,22(2)：77-79.
[58]刘剑刚,许勇钢,苏庆民.冠心病血瘀证的T细胞亚群、血脂和血液流变性改变及其相互关系[J].中国微循环,1999,3(4)：254.
[59]涂伟钦,张月菊.冠心病患者微量元素及自由基与中医辨证关系研究[J].天津中医药,2006,23(1)：37-38.
[60]莫鸿辉,潘佩光,黄衍寿,等.冠心病痰瘀证候与载脂蛋白E基因多态性相关性的研究[J].广州中医药大学学报,2010,27(4)：418-423.
[61]洪永敦,莫鸿辉,朱会英,等.ApoE血清水平及基因多态性与冠心病痰瘀证候关系的研究[J].新中医,2009,41(2)：42-44.
[62]赵冰,郭宏敏.老年冠心病痰瘀证ApoE基因多态性分布特点研究[J].山西中医,2008,24(10)：37-39.
[63]韩旭,李七一,赖仁胜,等.ApoE基因多态性与冠状动脉粥样硬化性心脏病中医证型的相关性研究[J].中华中医药学刊,2009,27(11)：2323-2330.
[64]欧阳涛,宋剑南,李林,等.冠心病痰瘀证候与载脂蛋白E第一内含子增强子基因多态性关系的 研究[J].中国中医基础医学杂志,2005,11(6)：414-417.
[65]吴依芬,周迎春,王刚,等.冠心病中医证型与GNB3基因C825T多态性的关联性分析[J].四川中医,2006,24(10)：23-25.
[66]吴依芬,周迎春,张学森.中国汉族男性冠状动脉粥样硬化性心脏病患者中医证型与ABCA1基因R219K多态性的关联性[J].中国临床康复,2006,10(7)：7-9.
[67]黄献平,袁肇凯,毛以林,等.冠心病血瘀证凝血因子Ⅶ基因多态性的检测分析[J].中西医结合心脑血管病杂志,2006,4(2)：97-99.
[68]毛以林,袁肇凯,黄献平,等.冠心病血瘀证与血管紧张素转换酶基因多态性的相关性研究[J].中国中西医结合杂志,2004,24(9)：776-780.
[69]朱会英.冠心病痰瘀证与C-反应蛋白、E-选择素水平及其基因多态性关系研究[J].广州：广州中医药大学,2007.
[70]王东生,袁肇凯.冠心病痰瘀辨证与外周血单核细胞PDGF-A mRNA表达的关系[J].安徽中医学院学报,2003,22(2)：14-16.
[71]王阶,杨保林,姜燕.冠心病血瘀证相关基因研究[J].世界科学技术-中医药现代化,2005,7(1)：16-19.
[72]李炜弘,王米渠,王刚,等.冠心病心阳虚证相关差异表达基因分析[J].现代中西医结合杂志,2004,13(24)：3219-3222.
[73]朱新星,张进军.冠心病不同虚证与血气分析关系的研究[J].中国医学工程,2005,13(2)：207-208.
[74]褚田明,顾仁樾.冠心病阳虚证与心功能减退关系的研究——附262例临床资料[J].江苏中医药,2007,39(6)：17-18.
[75]姜洪茹,郭勇.超声评价左心室收缩功能与冠心病实证者辨证分型关系初探[J].中国医药导报,2007,4(14)：20-21.
[76]刘辛光.冠心病辨证分型与血液动力学流变学变化关系探析[J].辽宁中医杂志,2005,46(6)：991.
[77]陈伯钧,张文清,张敏州.冠心病中医分型与心律失常及心功能关系分析[J].现代中西医结合杂志,2000,9(19)：1857-1858.
[78]刘雪梅,蒋红红,陈征宇,等.冠心病中医辨证分型与心电图关系的相关研究[J].河南中医学院学报,2009,24(143)：67-68.
[79]李方洁,白净,杨新春,等.心率变异性非线性特征与冠心病虚实证候相关性研究[J].辽宁中医杂志,2008,35(9)：1306-1308.
[80]宋娅萍.冠心病QT、JT离散度与中医证型关系分析[J].中国中医急症,2008,17(8)：1097-1099.
[81]谢慧文,张伟,孙敬和.冠心病中医证型与心电图QRS波群离散度的关系[J].上海中医药大学学报,2007,21(2)：31-33.
[82]杜廷海,朱明军,程江涛,等.冠心病中医证型与心电信息相关性的初步观察[J].中西医结合心脑血管病杂志,2006,4(1)：8-9.
[83]丁邦晗,杨敏,周珂,等.胸痹心痛患者心电图改变与中医证型的关系[J].中国中西医结合急 救杂志,2008,15(1)：31-33.
[84]王润桃,王硕仁,邢雁伟.血瘀证与心电图异常的关系[J].中医杂志,2006,46(6)：418.
[85]张宁宁,尹承娥,吕芳芳,等.气滞血瘀、气虚血瘀心绞痛患者心率变异性与心肌缺血指数相关性探讨[J].山东中医药大学学报,2003,27(2)：123-124.
[86]王玉燕,杜武勋,魏营,等.冠心病不同证型与颈动脉内-中膜厚度关系的研究[J].山西中医,2009,25(2)：34-36.
[87]杨东辉,孙博,郭艳艳.冠心病患者中医证型与颈动脉内膜-中层厚度及踝臂指数的相关性研究[J].云南中医中药杂志,2009,30(9)：5-6.
[88]程康林,覃勇,陈仁山,等.痰浊型冠心病患者痰浊证与颈动脉斑块的相关性分析[J].新中医,2006,38(8)：20-21.
[89]贾玉柱,沈盛晖,祁克信,等.冠心病中医证候与16层螺旋CT冠状动脉造影的相关性分析[J].中国中医急症,2010,19(10)：1703-1704.
[90]沈培红,毛威,叶武,等.64层螺旋CT冠脉成像与胸痹证型的相关性研究[J].中华中医药学刊,2010,28(6)：1224-1226.
[91]潘涛,宫剑滨,郭华,等.冠心病中医证型与冠状动脉双源CT成像相关性研究[J].中西医结合心脑血管病杂志,2007,5(10)：914-916.
[92]谷旭放.冠心病心绞痛气虚血瘀证与气滞血瘀证平板运动试验结果对照分析[J].中国全科医学,2010,13(6A)：1808-1812.
[93]张玉辉,毛静远,王占武,等.冠心病心绞痛气阴两虚及兼痰瘀证平板运动试验结果对照分析[J].中国中西医结合杂志,2005,25(4)：315-319.
[94]杜健鹏,史大卓,李田昌,等.冠心病稳定期血瘀证与冠状动脉病变特点的相关性[J].中西医结合学报,2010,8(9)：848-852.
[95]朱萱萱,王广基,达庆国,等.冠心病中医证型与冠状动脉造影的相关性研究[J].中华中医药学刊,2010,28(8)：1579-1581.
[96]任毅,陈可冀,张敏州,等.405例冠心病患者冠状动脉造影结果与中医证型的相关性[J].中医杂志,2010,51(8)：725-728.
[97]王振裕,时亮,陈嘉兴,等.冠心病患者中医证候与冠状动脉造影相关性研究[J].中华中医药杂志,2009,24(9)：1194-1197.
[98]杨阳,李方洁,杨新春,等.冠心病中医证候及脾虚痰浊证与冠脉病变的关系对比观察[J].中华中医药杂志,2010,25(3)：352-354.
[99]朱翠玲,闫奎坡,朱明军,等.冠心病中医证型与冠状动脉病变的相关性研究[J].中国中药杂志,2009,34(24)：3289-3291.
[100]邢雁伟,李尊,王阶,等.冠脉病变特征和中医证候要素关系的研究[J].辽宁中医杂志,2008,35(1)：36-38.
[101]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的血浆代谢组学研究[J].新中医,2010,42(6)：12-14.
[102]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国 中医基础医学杂志,2010,16(2)：126-128.
[103]华何与,贾钰华,张红栓,等.冠心病心绞痛三种血瘀证的血浆代谢组学研究[J].热带医学杂志,2010,10(3)：258-260.
[104]王广基,阿基业,严蓓,等.代谢组学研究冠心病中医分型的体内物质基础[J].世界科学技术—中医药现代化,2009,16(8)：127-133.
[105]赵慧辉,陈建新,史琦,等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究[J].中国中西医结合杂志,2010,30(5)：488-492.
[106]王阶,汤艳莉,何庆勇.冠心病心绞痛患者证候要素与生存质量的相关性[J].中医杂志,2010,51(2)：154-163.
[107]金明华,秦鉴,吴伟康,等.513例冠心病患者心绞痛类型与中医证型关系的研究[J].中医杂志,2009,50：185-186.
[108]杨俊华,杨国靖,刘茹.冠心病患者A型性格与情绪障碍及中医辨证分型关系的探讨[J].中国中医药信息杂志,2009,16(8)：23-25.
[109]西原辰一,史载祥,酒谷薰.应用可视光组织氧监测评价冠心病血瘀证舌诊的研究[J].中西医结合心血管病杂志,2009,7(11)：1274-1276.
[110]史载祥,武泽民,许树强.冠心病血瘀证病人舌分光定量以及舌表浅血流量观察[J].中西医结合杂志,1991,11(7)：407.
[111]李绍芝.心气虚病之脉图参数的初步观测[J].中医杂志,1987,28(1)：9.
[1]Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med,2001,345(7): 494-502.
[2]Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J]. Lancet,2001,358(9281):527-533.
[3]Steinhubl SR, Berger PB, Mann JT Ⅲ, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[4]Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction:randomised placebo-controlled trial[J]. Lancet,2005, 366 (9497):1607-1621.
[5]Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme:rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease[J]. Eur Heart J,2000,21 (24): 2033-2041.
[6]Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome:the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial[J]. Circulation,2004,110 (10):1202-1208.
[7]Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy formyocardial infarction with ST-segment elevation[J].N Engl J Med, 2005,352 (12):1179-1189.
[8]Kazui M, Nishiya Y, Ishizuka T, et al. Identif ication of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos,2010,38(1):92-99.
[9]Wiviott SD, Antman EM. Clopidogrel resistance:a new chapter in a fast-moving story [J]. Circulation,2004,109:3064-3067.
[10]Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel:a review of the evidence[J]. J Am Coll Cardiol.2005,45(8):1157-1164.
[11]Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost,2003,89:783-787.
[12]Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J]. Circulation,2004,109: 166-171.
[13]Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation,2003,107:2908-2913.
[14]Wenaweser P, Dorffler Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy [J]. J Am Coll Cardiol,2005,745 (11):1748-1752.
[15]Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNowHP2Y12 cartridge for monitoring platelet inhibition with clopidogrel[J]. Methods Find Exp Clin Pharmacol,2006, 28 (5):315-322.
[16]Laurent B, Laurence CJ. Adjusted clopidogrel loading doses according to vasodilator stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel res i stance [J]. Am Coll Cardiol,2008, 51(14):1404-1411.
[17]Schumann A, Wiesenburg A, Bucha E, et al. Platelet Adhesion Assay (PADA), a new quantitative test for assessment of platelet function and the apeutic drug monitoring of GPⅡb/Ⅲa and ADP receptor antagonists [J]. Hamostaseologie,2004,24(3):211-216.
[18]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J,2004,25(6):476-483.
[19]Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption[J]. Clin Pharm acol Ther,2006,80(5):486-501.
[20]Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
[21]Coutts RT, Unchuk LJ. Polymorphic cytochromes p450 and drugs used in psychiatry[J]. Cell Mol Neurobiol,1999,19(3):325-354.
[22]Wedlund PJ. The CYP2C19 enzyme polymorphism[J]. Pharm acology,2000,61(3):174-183.
[23]Hulot JS, Bura A, Villard E, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood,2006, 108(7):2244-2247.
[24]Miao J, Liu R, Li Z. Cytochrome P-450 polymorphisms and response to clopidogrel [J].N Engl J Med,2009,360(21):2250-2251.
[25]Trenk D, Hochholzer W, FrommM F, et al. Cytochrome P4502C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol,2008,51(20):1925-1934.
[26]Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss of function polymorphism, but not CYP3A4IVS10+12GPA and P2Y12 T744C polymorphisms, is associated with response variability to dual、antiplatelet treatment in high risk vascular patients[J]. Pharmacogenet Genomics,2007,17(12):1057-1064.
[27]Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study[J]. Lancet,2009, 373(9660):276-278.
[28]Angiolillo DJ, Ferna' ndez-Ortiz A, Bernardo E, et al. Contributio of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel[J]. A rterioscler Thromb Vase Biol,2006,26(8):1895-1900.
[29]Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel[J]. CMAJ,2006,174(12): 1715-1722.
[30]Smith SM, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy[J]. Platelets,2006,17(4):250-258.
[31]Brandt JT, Close SL, IturriaSJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J]. J Thromb Haem ost,2007,5(12):2429-2436.
[32]Cavallari U, Trabetti E, Malerba G, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease[J]. BMC M ed Genet,2007,8: 59.
[33]Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2 haplotype is associated with peripheral arterial disease:a case-control study[J]. Circulation,2003,108(24):2971-2973.
[34]Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease[J]. Stroke,2005,36(7):1394-1399.
[35]Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600mg loading dose of clopidogrel in 597 patients with non-ST segment elevation acute coronary syndrome[J]. Thromb Res,2007,120(6):893-899.
[36]Malek LA, Bartlomiej MD, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel [J]. Circulation, 2008,72(7):1165-1169.
[37]Schettert IT, Pereira AC, Lopes NH, et al. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease [J]. Thromb Res,2006,118(6): 679-683.
[38]Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation,2003,107 (1):32-37.
[39]Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet functiona flow cytometry study [J]. Ear Heart J,2003,24 (19):1744-1749.
[40]Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy[J]. Eur J Clin Invest,2005,35 (8):476-481.
[41]Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel[J]. Circulation,2003,108 (18):2195-2197.
[42]Gorehakova 0, von Beckerath N, Gawas M, et al. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting[J]. Eur Heart J,2004,25 (21): 1898-1902.
[43]Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial[J]. Circulation,2003,108 (8):921-924.
[44]Serrano Junior CV, Soeiro Ade M, Araujo LF, et al. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation[J]. Arq Bras Cardiol,2010,95(3): 321-327.
[45]Han YL, Zhang ZL, Li Y, et al. Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting:a randomized controlled trial[J]. Zhong hua Yi Xue Za Zhi,2009,89(32):2240-2244.
[46]Blagojevic A, Delaney JA, Levesque LE, et al. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention:a cohort study[J]. Pharmacoepidemiol Drug Saf,2009,18(5):362-369.
[47]Shen J, Zhang RY, Zhang Qet al. Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina[J]. Zhong Hua Xin Xue Guan Bing Za Zhi,2008,36(9):807-811.
[48]Geisler T, Zttrn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Eur Heart J,2008,29(13):1635-1643.
[49]董红娟,刘治军,傅得兴.他汀药物对氯毗格雷抗血小板活性影响的研究进展[J].中国药师,2009,12(3)：324-327.
[50]ISHZAKI T.HORAI Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole[J]. Alinment Pharmacol Ther,1999,13:27-36.
[51]EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS WE. Pharmacogenomics and individualized drug therapy[J]. Annu Rev Med,2006,57:119-137.
[52]GARDINER J, BEGG J. Pharmacogenetics, drug-metabolizing enzymes, and clinical pratice[J]. Pharmacol Rev,2006,58(3):521-590.
[53]Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009,180 (7):713-718.
[54]Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA, 2009,301 (9):937-944.
[55]Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101 (4):714-719.
[56]Havranek EP, Weinberger J. Concomitant use of angiotensin converting enzyme(ACE) inhibitors and antiplatelet therapies:clopidogrel versus aspirin [J]. J Hypertens,1999, 17:S57.
[57]De Miguel A, Ibanez B, Badimon JJ, et al. Clinical implications of clopidogrel resistance[J]. Thromb Haemost,2008,100(2):196-203.
[58]Serebruany VL. The "clopidogrel resistance" trap[J]. Am J Cardiol,2007,100(6): 1044-1046.
[59]Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina [J]. Catheter Cardiovasc Interv, 2003,59 (1):21-25.
[60]谭丽玲,贾三庆,王明生,等.急性冠脉综合征患者氯吡格雷抵抗的影响因素[J].中国心血管病研究杂志,2006,4(9)：680.
[61]SluggPH, Much DR, Smith WB, et al. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel[J]. J Clin Pharmacol,2000,40(4):396-401.
[62]Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose[J].Thromb haemost,2004,92:311-316.
[63]Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel [J]. J Intern Med,2002,252 (3)：233-238.
[64]Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance:role of body mass and concomitant medications[J]. Int J Cardiol,2007,120 (2):188-192.
[65]Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation,2004,109 (25):3171-3175.
[66]Lev El, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J]. J Am Coll Cardiol,2006,47 (1):27-33.
[67]Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetesmellitus and coronary artery disease[J]. J Am Coll Cardiol,2007,50(16):1541-1547.
[68]Westerbacka J, Yki-jarvinen H, Turpeinen A, et al. Inhibition of platelet collagen interaction:an in vivo action of insulin abolished by insulin resistance in obesity[J]. Arterioscler Thromb Vase Biol,2002,22 (2):167-172.
[69]Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors inmedically treated patients with coronary disease [J]. Int J Obes (Lond),2008,32(6):967-974.
[70]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J,2004,25 (6):476-483.
[71]Pozgajovd M, Sachs UJ, Hein L, et al. Reduced thrombus stability in mice lacking the alpha2A-adrenergic receptor[J]. Blood,2006,108(2):510-514.
[72]Beres BJ, Toth-Zsdmboki E, Vargovd K, et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy[J]. Thromb Haemost,2008,100(5):829-838.
[73]Maayani S, Schwarz T, Craddock-Royal B, et al. Activation of the alpha (2A)-adrenoceptormediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro[J]. Platelets,2001,12(6):359-375.
[74]Dziewierz A, Dudek D, Heba G, et al. Interindividual variability in response to clopidogel in patients with coronary artery disease[J]. KardiolPol,2005,62(2):108-117.
[75]Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptif ibatide to arrest the reactivity of platelet:results of the Clopidogrel Loading With Eptif ibatide to Arrest the Reactivity of Platelet (CLEAR PLATELETS)study[J]. Circulation,2005,111:1153-1159.
[76]von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-,600-, and 900-mg loading doses of clopidogrel:results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen:Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial[J]. Circulation,2005,112(19): 2946-2950.
[77]Yong G, Rankin J, Ferguson L, et al. Randomized trial comparing 600-with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention:results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL)Trial[J]. Am Heart J,2009,157(1):60el-69el.
[78]张建维,贾三庆,曹树军,等.不同负荷量的氯吡格雷对急性冠脉综合征患者血小板聚集功能及氯吡格雷抵抗发生率的影响[J].实用医学杂志,2007,23(1)：60-69.
[79]Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300 and 450mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation[J]. Am Heart J,2002,143(1):118-123.
[80]Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting:effects on drug response and interindividual variability[J]. Eur Heart J,2004,25:1903-1910.
[81]Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting [J]. J Am Coll Cardiol,2006,48: 1339-1345.
[82]Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel:the PRINC(Plavix Response in Coronary Intervention)trial[J]. JACC Cardiovasc Interv,2008,1(6):612-619.
[83]Sprigg N, Gray LJ, England T, et al. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility[J]. PLoS ONE,2008,3(8):e2852.
[84]Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome [J]. JAMA,2008,299(5): 532-539.
[85]Danzi GB, Capuano C, SesanaM, et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein Ⅱb/Ⅲa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention[J]. Am J Cardiol,2006,97(4): 489-493.
[86]De Servi S, Mariani M, Vandoni P, et al. Use of glycoprotein Ⅱb/Ⅲa in hibitors in invasively-treated patients with non-ST elevation acute coronary syndrome [J]. J Cardiovasc Med (Hagerstown),2006,7(3):159-165.
[87]Fitchett DH, Langer A.Armstrong PW, et al. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein Ilb/IIIa inhibitor eptif ibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment(INTERACT) trial[J]. Am Heart J,2006,151(2):373-379.
[88]Curran MP, Keating GM. Eptif ibatide:a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention[J]. Drugs,2005,65(14): 2009-2035.
[89]Puma JA, Banko LT, Pieper KS, et al. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting:insights from the Enhanced Suppression of the Platelet Ilb/IIIa Receptor With Integrilin Therapy(ESPRIT)trial[J]. J Am Coll Cardiol,2006,47(4):715-718.
[90]Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate-to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide:observations from the PROTECT-TIMI-30 trial [J]. J Am Coll Cardiol,2006,47(12): 2374-2379.
[91]0'Naill WW, Serruys P, Knudtson M, et al. Long-term treatment with Aplatelet glycoprotein2recep torantagonist after percutaneous coronary revascularization [J]. N Engl J Med,2000,342 (17):1316-1324.
[92]The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes[J]. Circulation,2001,103(13): 1727-1733.
[93]Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Circulation,2009,119(25):3207-3214.
[94]King SB, Smith SC, Hirshf eld JW, et al.2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention [J]. Circulation,2008,117(2):261-295.
[95]Pothiwala RA, TanwarNS, Ranjan A, et al. Efficacy and safety of high loading dose clopidogrel regimen prior to coronary stent implantation [J]. Indian Heart J,2004,56:A496.
[96]Brandt JT, Payne CD, Weerakkody G, et al. Superior responder rate for inhibition of platelet aggregation with a 60mg loading dose of prasugrel (CS2747, LY640315) compared with a 300 mg loading dose of clopidogrel[J]. J Am Coll Cardiol,2005,45:87A.
[97]Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS2747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity [J]. Semin Thromb Hemost,2005,31:184-194.
[98]Peters G, Robbie G. Single dose pharmacokinetics and pharmacodynamics of AZD6140:an oral reversible ADP receptor antagonist[J]. Hematologica,2004,89:14-15.
[99]Husted S, Emanuelsson H, Heptinstall S,et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:a double-blind comparison to clopidogrel with aspirin[J]. Eur Heart J, 2006,27:1038-1047.
[1]贺铁豪,高国政,张奇峰.脑心通胶囊治疗冠心病心绞痛40例[J].辽宁中医杂志,2010,37(5)：866-867.
[2]刘静秋.步长脑心通治疗冠心病心绞痛疗效观察[J].中国社区医师,2010,12(227)：73.
[3]马晓梅,赵占丽.脑心通胶囊治疗冠心病心绞痛32例临床观察[J].首都医药,2010,(12)：55-56.
[4]陈明清,王柽鑫,李玉华,等.步长脑心通胶囊长期治疗冠心病的临床疗效观察[J].医学实践与理论,2010,23(4)：402-403.
[5]邱清华,彭玉玺,齐昕,等.步长脑心通和辛伐他汀预防冠心病合并糖尿病冠状动脉支架内再狭窄的疗效观察[J].当代医学,2010,16(5):29-30.
[6]姚品芳.丹红注射液联合脑心通治疗无症状性心肌缺血的临床疗效观察[J].当代医学,2009,15(34)：139-140.
[7]卫海松,高海旺,王亮亮,等.步长脑心通胶囊治疗冠状动脉慢血流的临床研究[J].慢性病学杂志,2010,12(9)：1019-1020.
[8]贺志伟,李力明,邹迪贵,等.脑心通对急性心肌梗死患者再灌注后心肌和微血管的影响观察[J].中国实用医药,2010,5(17)：166-168.
[9]张志诚,刘建华,林振起,等.脑心通胶囊对急性冠脉综合征患者颈动脉斑块和血清超敏c反应蛋白的影响[J].中医杂志,2010,51(4)：329-331.
[10]张兆源.脑心通对急性冠脉综合征相关因子影响的研究[J].人民军医,2010,53(12)：926-927.
[11]关良劲,钟汉林,王珊,等.步长脑心通对急性冠状动脉综合征血清基质金属蛋白酶及其抑制物水平的影响[J].岭南急诊医学杂志,2007,12(6)：414-415.
[12]杨国栋,高天宇.步长脑心通改善冠心病左心功能的临床研究[J].内蒙古中医药,2008,3：5-6.
[13]陈勇,缪灿铭,陈正贵,等.脑心通治疗老年心力衰竭的疗效观察[J].中西医结合心脑血管病杂志,2005,3(7)：603-604.
[14]胡美琴,崔伟娜,徐玉兰.脑心通对肥胖原发性高血压瘦素水平影响的研究[J].人民军医,2010,54(1)：36-37.
[15]王莹,吴相得,贾连旺.脑心通胶囊对老年单纯收缩期高血压血管内皮舒张功能影响的超声评价[J].中华中医药学刊,2008,28(3)：657-659.
[16]颜文涛.步长脑心通治疗老年人原发性高血压的临床疗效观察[J].实用心脑肺血管病杂志,2008,16(11)：34.
[17]孟秀清.脑心通治疗脑梗死疗效观察[J].亚太传统医药,2010,6(9)：32-33.
[18]张天华,王松龄.步长脑心通胶囊治疗急性脑梗死的临床观察[J].光明中医,2010,25(10) ：1844-1845.
[19]刘建书,贺永红.脑心通治疗脑梗死的临床观察[J].中国民康医学,2010,22(10)：1258.
[20]何建明,李玉蓉,韦英秀,等.脑心通胶囊对急性脑梗死患者血清血管内皮细胞生长因子水平影响的研究[J].医学研究杂志,2010,39(11)：36-38.
[21]粟显才,伍玉锋.步长脑心通胶囊对短暂性脑缺血发作患者血清超敏C反应蛋白的影响[J].实用心脑肺血管病杂志,2010,18(10)：1447-1448.
[22]张月明,鲁东。王冶.步长脑心通联合阿司匹林治疗短暂性脑缺血发作疗效观察[J].中国当代医药,2010,17(13)：104-105.
[23]钟玲.脑心通胶囊配合醒脑开窍针刺法治疗脑血管病偏瘫临床研究[J].辽宁中医杂志,2010,37(7)：1288-1289.
[24]杨志军.脑心通胶囊结合康复疗法对缺血性脑卒中恢复期的疗效验证[J].吉林医学,2010,31(5)：617-618.
[25]高立,张宗艳,王莉,等.脑干听觉诱发电位和经颅多普勒超声对脑心通治疗椎基底动脉短暂缺血性眩晕的疗效观察[J].临床荟萃,2010,25(20)：1809-1811.
[26]张秀忠,张德新,徐海樱.步长脑心通在缺血性脑血管病二级预防中的疗效观察[J].实用心脑肺血管病杂志,2008,16(12)：37.
[27]葛近峰,何爱芳,宁子秀.步长脑心通胶囊合高压氧治疗血管性痴呆36例[J].辽宁中医杂志,2010,37(6)：1050-1051.
[28]冯辉,张雪梅,刘彩莉.步长脑心通联合丁咯地尔治疗血管性痴呆临床观察[J].辽宁中医药大学学报,2008,10(10)：88-90.
[29]蔡敏,马绿曦,罗春阳,等.步长脑心通治疗血管性痴呆的临床分析[J].重庆医学,2008,37(21)：2453-2454.
[30]郭宝珠.步长脑心通治疗118例冠心病合并高血脂患者疗效分析[J].青海医药杂志,2010,40(8)：12-13.
[31]韩知.步长脑心通配合足浴治疗糖尿病周围神经病变疗效观察[J].亚太传统医药,2010,6(9)：37-38.
[32]仲崇涛,闫洪泉.丹红注射液加脑心通胶囊治疗Ⅰ期糖尿病足疗效观察[J].人民军医,2010,53(9)：687-688.
[33]姜凤琴,宗高庚,许道营,等.脑心通对2型糖尿病微血管病变患者血小板活化功能的影响[J].山东医药,2007,47(13)：58.
[34]戴铁军.脑心通配合西药治疗2型糖尿病视网膜病变24例临床观察[J].云南中医中药杂志,2007,28 (7)： 12.
[35]张书申,王芳,乔苏民.脑心通胶囊联合福辛普利治疗早期糖尿病肾病[J].中国中西医结合心脑血管病杂志,2007,5(12)：1180-1181.
[36]郭立东,穆克代斯,桑晓红.步长脑心通胶囊对慢性肾炎患者的血流变及血脂的影响[J].中国实用医药,2008,3(11):44-45.
[37]罗玉军.步长脑心通治疗痔疮的疗效观察[J].实用医技杂志,2007,14(13)：1807.
[38]万敏娜,金钟奎,万洁华,等.脑心通胶囊在治疗慢性肺源性心脏病的临床研究[J].中国实用 医药,2010,5(20)：163-164.
[39]王振峰,张华,崔之娟,等.步长脑心通胶囊治疗紧张性头痛的远期疗效观察[J].中国医药导报,2010,7(10)：109-110.